THERMAL-XR(R) Sales in the United States to Commence After GMG Receives U.S. EPA Approval

Brisbane, Australia--(ACN Newswire via SeaPRwire.com. - March 16, 2026) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that the United States Environmental Protection Agency ("EPA") has now approved the import and sale of GMG's THERMAL-XR graphene based coating system in the United States.The EPA has issued a consent order for pre-manufacture notice PMN P-25-0018 in accordance with section 5(e) of the Toxic Substances Control Act, 15 U.S.C. 2604(e) (the "Order"). Under the Order, GMG is authorised to export, distribute, sell, use and dispose of the chemical substance described in the pre-manufacture notice submitted by the Company, and which is used in GMG's THERMAL-XR® ENHANCE graphene-based coating system for various applications including Heating Venting Air Conditioning and Refrigeration (HVAC-R), Data Centres, Liquified Natural Gas Plants (LNG), Automotive and Electronics amongst others in the United States in accordance with the requirements and conditions set out in the Order (the "New Chemical Substance").GMG supplies its THERMAL-XR® graphene coating product for the HVAC-R equipment market to its exclusive North American distributor, Nu-Calgon Wholesaler, Inc. ("Nu-Calgon") which is marketed and sold as "Nu-Calgon CoolWorx® powered by GMG® Graphene" as seen in an example shown in Figure 1. As a result of the Order, GMG, together with Nu-Calgon, is now able to commence commercial sales of THERMAL-XR® products into the U.S. for industrial use, subject to and in accordance with the requirements and conditions of the Order.Figure 1: Nu-Calgon CoolWorx® Powered by GMG® Graphene LabelTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/288616_ab987720443d2967_001full.jpgThe first shipment of THERMAL-XR® will now be sent to Nu-Calgon for distribution in North America.Craig Nicol, CEO & Managing Director of the Company, commented, "We believe that this EPA consent order is a major milestone for GMG as it allows us, together with our exclusive North American distributor Nu-Calgon, to commence commercial sales of THERMAL-XR® in we what we see as the largest HVAC-R coating market in the world."Jack Perkowski, Chairman and Non-Executive Director of the Company, commented: "With regulatory clearance now in place, we believe that we can begin converting the strong interest that we have seen from customers into revenue, while leveraging Nu-Calgon's extensive distribution network to reach across the North America to scale THERMAL-XR® ENHANCE / CoolWorx® deployment over time. We believe that GMG is one of the few companies to have received EPA approval for the export and sale of an unlimited amount of a graphene-based product in the United States of America."About THERMAL-XR® ENHANCE powered by GMG Graphene:THERMAL-XR® ENHANCE coating system is a unique method of improving the conductivity of corroded heat exchange surfaces and improving and maintaining the performance of new units at peak levels. The process coats and protects heat exchange surfaces while improving and rebuilding the lost corroded thermal conductivity and increasing the heat transfer rate by leveraging the physics of GMG Graphene, resulting in an efficiency improvement and a potential power reduction.THERMAL-XR® ENHANCE is now patented for 20 years in Australia and is expected to be patented in other countries around the world.THERMAL-XR® ENHANCE Development and EPA Approval HistoryMonthSignificant Milestones for THERMAL-XR® powered by GMG GrapheneSeptember2022GMG acquires THERMAL-XR® manufacturing intellectual property and brand rights GMG ACQUIRES THERMAL-XR MANUFACTURING INTELLECTUAL PROPERTY AND BRAND RIGHTS AND GRANTS RSUs TO DIRECTORS AND OFFICERS - Graphene Manufacturing Group | GMG (graphenemg.com)December2022Verified Improved Heat Transfer by The University of Queensland. VERIFIED IMPROVED HEAT TRANSFER ON ALUMINIUM WITH THERMAL-XR® & MARKET UPDATE - Graphene Manufacturing Group | GMG (graphenemg.com)February2023Approval from Australian Industrial Chemicals Introduction Scheme (AICIS) GMG RECEIVES REGULATORY APPROVAL TO ENABLE SIGNIFICANT COMMERCIAL SALES - Graphene Manufacturing Group | GMG (graphenemg.com)April 2023Total available market for THERMAL-XR® estimated by Company to be > US$28.4 billion GMG ANNOUNCES COMMERCIALISATION PROGRESS OF THERMAL-XR® - Graphene Manufacturing Group | GMG (graphenemg.com)April 2023First order of THERMAL-XR® > $120,000 GMG ANNOUNCES COMMERCIALISATION PROGRESS OF THERMAL-XR® - Graphene Manufacturing Group | GMG (graphenemg.com)May 2023Signing of Distributors for Singapore, Thailand, Indonesia & South Korea GMG SIGNS THERMAL-XR® DISTRIBUTOR AGREEMENTS IN 4 ASIAN COUNTRIES - Graphene Manufacturing Group | GMG (graphenemg.com)June 2023Independently Verified Heat Transfer & Energy Savings GMG ANNOUNCES INDEPENDENTLY VERIFIED HEAT TRANSFER AND ENERGY SAVINGS RESULTS FROM THERMAL-XR® - Graphene Manufacturing Group | GMG (graphenemg.com)July 2023Signing of Nu-Calgon Distribution for North America - USA, Canada, Mexico, & Caribbean. GMG APPOINTS NU-CALGON AS THERMAL-XR® DISTRIBUTOR FOR NORTH AMERICA - Graphene Manufacturing Group | GMG (graphenemg.com)August2023Commissioning of THERMAL-XR® Coating Bulk Blend Plant GMG PROVIDES COMMERCIALISATION PROGRESS OF THERMAL-XR® - Graphene Manufacturing Group | GMG (graphenemg.com)October2023Forward Orders > AU$ 400k - Conditional on Import Approvals for some Countries GMG PROVIDES COMMERCIALISATION UPDATE ON ENERGY SAVINGS COATING THERMAL-XR® - Graphene Manufacturing Group | GMG (graphenemg.com)December2023Commissioning of the modular Graphene Production plant Graphene Manufacturing Group Commissions Modular Graphene Production Plant - Graphene Manufacturing Group | GMG (graphenemg.com)January2024Canada Approval Department of Environment and Climate Change Canada (ECCC)January2024Launch of Nu-Calgon CoolWorx® powered by GMG Graphene at Chicago AHR Expo 2024. Launch of Nu-Calgon CoolWorx® powered by GMG Graphene at Chicago AHR Expo 2024.April 2024GMG Provides Commercialisation Update on Energy Savings Coating THERMAL-XR® GMG Provides Commercialisation Update on Energy Savings Coating THERMAL-XR®December2024GMG Reaches Market Commercialisation Milestone on Energy Savings Coating THERMAL-XR® GMG Reaches Market Commercialisation Milestone on Energy Savings Coating THERMAL-XR®December2025USA EPA Approval Conditions Accepted for Graphene Coating THERMAL-XR® USA EPA Approval Conditions Accepted for Graphene Coating THERMAL-XR® About GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed at improving the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information, please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and U.S. securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "believes" "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, GMG and Nu-Calgon's ability to leverage Nu-Calgon's distribution network to commence commercial sales of THERMAL-XR® ENHANCE-based products into the U.S. HVAC-R aftermarket, intentions as to the first shipment of THERMAL-XR® ENHANCE, the intended focus of initial THERMAL-XR® ENHANCE deployment, the energy efficiency, decarbonisation and corrosion protection benefits of THERMAL-XR® ENHANCE, GMG's intention to work with the EPA and GMG's intention to progress its broader THERMAL-XR® ENHANCE commercialisation activities.Such forward-looking statements are based on a number of assumptions of management, including the receipt of a fully signed consent notice from the EPA. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation that GMG does not receive or receive on a timely basis the fully signed consent notice from the and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 4, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/288616 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-16

FWD Group delivers record full year 2025 results with profitable growth, improved capital and cash flow generation

HONG KONG, Mar 16, 2026 - (ACN Newswire via SeaPRwire.com) – FWD Group Holdings Limited (“FWD Group” or “FWD”) today announced its first set of full-year results as a Hong Kong listed company for the 12 months ended 31 December 2025.- New business sales were up 25 per cent to US$2.446 billion compared to 2024 on an annualised premium equivalent (APE) basis. New business contractual service margin (CSM) was US$1.476 billion, with year-on-year growth of 18 per cent.- Operating profit after tax was up five per cent to US$499 million with positive contributions from each of the company’s four geographic reporting segments – Hong Kong SAR & Macau SAR; Thailand & Cambodia; Japan; and Emerging Markets.- Net profit of US$166 million is a record IFRS 17 result and for the second consecutive year, FWD Group was operating cash flow positive as at 31 December 2025. Leverage ratio reduced to 21.3 per cent approaching the company’s target range of 15-20 per cent.- Significantly increased important indicators of shareholder value creation, with comprehensive tangible equity (CTE) up 18 per cent to US$8.72 billion compared to 31 December 2024 and Group embedded value (EV) up 19 per cent year-on-year to US$6.85 billion. A strong capital position was maintained with a 265 per cent solvency ratio^.- In December 2025, FWD Group was added to the Hang Seng Composite Index and the eligible securities list for the Stock Connect programme, where Mainland Chinese investors connect via the Shanghai Stock Exchange and Shenzhen Stock Exchange with Hong Kong market opportunities via a southbound trading mechanism. FWD Group was also included in the MSCI Hong Kong Small Cap Index in February 2026.Huynh Thanh Phong, Group Chief Executive Officer and Executive Director of FWD Group, said, “2025 was a stand-out year for FWD Group. We successfully executed our customer-led strategy, underpinned by our digitally enabled business model. Record financial results were achieved. And of course, we began trading as a publicly listed company, following our July 2025 initial public offering. This fulfilled a long-held objective to ensure FWD Group has full capital market access, as a solid foundation for our future development and growth.”The strong 2025 results were driven by organic growth across most of the 10 Asian markets where FWD Group operates, with a particularly outstanding performance in the Hong Kong SAR & Macau SAR segment.A solid performance was posted in Japan, in a year where FWD began to diversify beyond its successful protection business into the retirement and savings segment, with its first offering – a yen-denominated single premium variable annuity product.As an established market leader in Thailand, FWD remains well positioned to grow quality new business in future, despite headwinds from a lower rate environment which impacted 2025 results, in addition to the 2024 exit from underwriting new business in the corporate care segment.Excellent growth was delivered in the Emerging Markets segment – which is comprised of five of the rest of FWD Group’s Southeast Asian markets – consistent with the longer-term demographic, wealth creation, and digital adoption trends in this region.“With 2026 already underway, we remain firmly focused on executing our strategy as we build for the future – operating with customers at the heart of everything we do in high-growth Asian markets, with a focus on long-term sustainability and profitability,” added Huynh Thanh Phong.About FWD GroupFWD Group (1828.HK) is a pan-Asian life and health insurance business that serves more than 38 million customers across 10 markets, including BRI Life in Indonesia. FWD’s customer-led and tech-enabled approach aims to deliver innovative propositions, easy-to-understand products and a simpler insurance experience. Established in 2013, the company operates in some of the fastest-growing insurance markets in the world with a vision of changing the way people feel about insurance. FWD Group is listed on the main board of the Hong Kong Stock Exchange under the stock code 1828.For more information, please visit www.fwd.comFor media inquiries, please contact: groupcommunications@fwd.comSource: FWD Group Holdings LimitedThe results are for the 12 months ended 31 December 2025 and are compared to the same period in 2024.Group LCSM cover ratio, group embedded value, comprehensive tangible equity values are December 2025 balances/ratios and growth rates are represented accordingly.Growth rates are represented on a constant exchange rate (CER) basis, unless otherwise stated.Except for operating profit/(loss) after tax (non-IFRS measure), net profit/(loss), and comprehensive tangible equity, all other numbers are unaudited. Operating profit after tax and net profit after tax represent the amounts attributable to equity holders of the company and are presented net of non-controlling interests. New business sales are calculated on an annualised premium equivalent (APE) basis, based on 100 percent annualised first year premiums and 10 percent single premiums. Comprehensive tangible equity is calculated as total equity of the Group attributable to shareholders of the Company plus contractual service margin (net of tax and non-controlling interests), minus intangible assets (net of non-controlling interests).* Actual exchange rate basis  ^ Prescribed capital requirement (PCR) basis Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-16

Bonus Savings Account: What It Is and How It Helps You Earn More Interest

SINGAPORE, Mar 16, 2026 - (ACN Newswire via SeaPRwire.com) - In a world where living costs continue to rise, making your money work harder for you is a necessity. While a standard savings account offers a base interest rate, a bonus savings account allows you to earn higher interest by meeting specific conditions.By understanding the mechanics of these accounts, you can turn your idle cash into a productive asset. This article explores the features of these accounts and how they can help you reach your financial goals sooner.What is a Bonus Savings Account?A bonus savings account is a type of bank account that rewards you with higher interest rates when you meet specific conditions. Unlike a basic account that pays a flat, low rate regardless of your activity, these accounts are designed to encourage healthy financial habits.Generally, your total interest is split into two parts: base interest and bonus interest. The base interest is what you earn on every dollar, regardless of your activity. The bonus interest is an additional percentage added when you fulfil certain requirements, such as increasing your monthly balance or spending on a linked credit card.How a Bonus Savings Account Helps You Earn MoreThe primary appeal of a bonus savings account is the ability to earn interest rates that are often several times higher than standard savings accounts. Here is how they help you maximise your earnings:1. Rewarding Consistent Savers: Many accounts reward you for not spending your money. For example, some accounts offer bonus interest if your monthly average balance increases compared to the previous month. This encourages you to keep your funds in the account rather than withdrawing them for impulsive purchases, allowing compounding to work in your favour.2. Consolidating Your Financial Activities: Banks often use a bonus savings account to reward loyalty. You might earn extra interest by linking your salary credit or meeting a minimum spend on the bank's credit cards. By centring your financial activities around one account, you can unlock higher tiers of interest than with a basic savings plan.3. Tiered Interest Structures: Most bonus accounts use a tiered system. This means that as your balance grows, the interest rate on specific brackets of your funds increases. This structure is particularly beneficial for those with growing savings, as it allows larger balances to earn higher rates.Common Requirements to Unlock Bonus InterestTo make the most of a bonus savings account, you need to understand the typical requirements. Banks in Singapore usually look for the following:Balance Growth: Maintaining or increasing your balance month on month.Salary Credit: Having your monthly take-home pay credited directly into the account via your employer.Spend Requirements: Using a linked debit or credit card for a minimum amount (often SGD 500) each month.Investing or Insuring: Purchasing eligible insurance or investment products through the bank.Is a Bonus Savings Account Right for You?While the high interest rates are attractive, a bonus savings account is most effective when it aligns with your natural spending and saving habits.If you are someone who saves a portion of your income every month and rarely withdraws from your reserves, an account that rewards balance growth is an excellent fit. However, if you prefer an account that doesn't require you to track credit card spending or investment tiers, you may want to consider a simpler savings account.Strategies to Maximise Your InterestTo ensure you never miss out on your bonus interest, consider these simple steps:Automate Your Savings: Set up a standing instruction to move a fixed amount into your bonus savings account every month. This ensures your balance grows consistently without you having to remember to do it manually.Track Your Monthly Average Balance: Be mindful of the mid-month balance rather than just the balance on the last day of the month. Large withdrawals in the middle of the month may lower your average balance.Consolidate Spending: If your account requires a minimum card spend, try to put all your essential costs, such as groceries, transport, and utilities, on that specific card to hit the target easily.Final ThoughtsA bonus savings account can be a useful tool for improving returns on your cash savings. It transforms the act of saving from a passive habit into a rewarding strategy. By choosing an account that fits your lifestyle and staying disciplined with the requirements, you can help your hard-earned money grow at a higher rate.Disclaimer: This article is for general information only and does not have any regard to the specific investment objectives, financial situation and particular needs of any specific person. The views expressed in this article are solely those of the author. This article shall not be regarded as an offer, recommendation, solicitation or advice. You may wish to consult your own professional advisers about this article, in particular, a financial professional before making financial decisions. Any past events, trends and/or performance referred to in this article may not necessarily be indicative of future events, trends or performance. This article is based on certain assumptions and reflects prevailing conditions as at the time of publication, which are subject to change at any time without notice. The author and publisher of this article as well as any other parties associated with this article make no representation or warranty of any kind, whether express, implied or statutory, in respect of this article and accept no liability or responsibility for the completeness or accuracy of this article or any error, inaccuracy or omission relating to this article and/or any consequence, injury, loss or damage howsoever suffered by any person relating to this article, in particular, arising from any reliance by any person on this article. Publishers or platforms may be compensated for access to third party websites.Contact Information:Name : Sonakshi MurzeEmail : Sonakshi.murze@iquanti.comJob Title : ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-16

China Lilang Announces 2025 Annual Results

HONG KONG, Mar 16, 2026 - (ACN Newswire via SeaPRwire.com) – China Lilang Limited (“China Lilang” or the “Company”, together with its subsidiaries, the “Group”; stock code: 1234) today announced its results for the year 2025.Mr. Wang Dong Xing, Chairman and Non-Executive Director of China Lilang, said: “In 2025, against a backdrop of steady macroeconomic recovery and moderate growth in the consumer market, the apparel industry in the Chinese Mainland maintained an overall stable development trajectory despite facing pressure. Amid the broader trend of consumption upgrading, the menswear market is undergoing structural differentiation, with mid-to-high-end segments such as business casual and smart casual becoming core growth drivers. The industry is accelerating its transition from 'quantity-driven competition' towards a stage of high-quality competition centered on 'innovation, quality and sustainable development. China Lilang deepened its presence in the menswear market with its differentiated brand matrix, building a diversified business portfolio through the 'LILANZ' core collection, the 'LESS IS MORE' smart casual collection and the 'MUNSINGWEAR' sports line, to comprehensively meet market demand for high-quality, diverse apparel. At the same time, the Group optimized its omni-channel marketing layout, strengthened online-offline operational synergies, actively expanded into emerging online platforms while accelerating the DTC model offline, and simultaneously advanced its internationalization strategy to enhance brand influence and operational efficiency across multiple dimensions.”During the year, the Group's revenue increased by 11.5% year-on-year to RMB4.07 billion. Revenue from the smart casual and other collections surged by 28.4%, primarily driven by a significant increase in average sales per store and the outstanding performance of new retail channels. Revenue from the core collection grew by 6.0%, mainly due to the initial operational efficiencies generated during the year following the Group's transition to a DTC model after reclaiming distribution rights from distributors starting last year.Gross profit margin increased by 1.9 percentage points year-on-year to 49.6%, mainly due to the increase in average unit price as a result of a higher proportion of direct-to-retail sales, coupled with a smaller one-off deduction from revenue arising from the recovery of distribution rights. Profit attributable to equity shareholders was RMB502 million (2024: RMB460 million), representing an increase of 9.0%. The profit margin attributable to equity shareholders decreased by 0.3 percentage points year-on-year to 12.6%. Earnings per share increased by 9.0% to RMB41.96 cents.The Board has recommended a final dividend of HK13 cents per share (2024: HK9 cents) and a special final dividend of HK3 cents per share (2024: HK3 cents). Together with the interim dividend already paid, the total dividend for the year amounted to HK32 cents per share, maintaining a stable dividend payout ratio.During the year, the Group adhered to its core strategy of ensuring a well-differentiated brand matrix and deepening its presence in the menswear market. The "LILANZ" core collection continued to consolidate its competitive advantage in the traditional menswear market. By optimizing product structure and deepening regional channel deployment and penetration, it further enhanced brand awareness and market share in key markets. Having successfully completed the repurchase and transformation of distribution rights in Northeast China and Jiangsu Province last year, the Group accelerated channel innovation throughout the year, subsequently acquiring the operating rights of first-tier distributors in Shandong Province and Chongqing City. The "LESS IS MORE" smart casual collection, targeting younger consumers, continued to operate under a fully direct-to-retail model, with its store opening strategy focused on shopping malls, which is preferred by consumers to enhance the consumer experience through a precisely tailored store image. As at the end of December 2025, there were 2,446 stores for the core collection and 371 stores for the smart casual and other collections, a total of 2,817 stores with a net increase of 44 stores.During the year, the Group continued to focus on opening stores in prime locations within premium shopping malls and outlet centers, attracting customers and boosting sales through distinctive brand-specific renovations. As at 31 December 2025, the number of stores located in shopping malls and outlet stores increased to 1,135 (31 December 2024: 1,036).The Group completed strategic transformation of its new retail business, upgrading it from an inventory clearance channel into a major new product sales platform. Revenue from this segment recorded a significant increase of 25% during the year. While continuing to strengthen its presence on mature sales platforms like Tmall, JD.com and TikTok, the Group has also expanded into emerging channels such as Pinduoduo, Wechat Channels and Poizon, creating a diversified online sales network altogether.  The Group made full use of social platforms such as Xiaohongshu and Weibo to continuously produce high-quality content to strengthen its content-driven e-commerce strategy. This approach not only deepened the emotional connection with consumers but also effectively expanded the young customer base, opening new growth opportunities for the new retail business.Regarding the "Multi-brands and Internationalization" development strategy, the premium golf apparel brand "MUNSINGWEAR", a key element of the Group's multi-brand strategy, successfully completed its transaction closing in the first half of the year. In the second half, it opened its first batch of physical stores in locations including Chongqing and Jinjiang, further enriching the Group's diversified brand portfolio and premium product lines. Meanwhile, the Group's plan to open its first store in Malaysia was successfully implemented and the first stores commissioned in May. In November, it opened the world's first "Future Retail" concept flagship store at Pavilion Bukit Jalil, a core business district in Kuala Lumpur. By the end of December 2025, 4 stores had been opened. The smooth operation of all stores not only completed the initial layout in the Southeast Asian market but also laid an important foundation for the Group’s subsequent expansion across the region.During the year, the Group adhered to its core design philosophy of "Simplicity but Not Simple", deepening proprietary research and development across its industrial chain. It implemented a core premium product strategy, focusing on fabric innovation, craftsmanship upgrades and standard-setting to strengthen its competitive advantage of "Technology-Empowered Products", while transforming its technological expertise into industry-wide reference standards.Facing a market environment where opportunities and challenges coexist, China Lilang will maintain a prudent yet optimistic stance and continue to pursue its core strategy of "Multi-brands and Internationalization". It will advance channel reforms, strengthen product innovation and enhance operational efficiency, to bolster its leading position in China's menswear industry. The Group plans for  a net increase of approximately 50 to 100 stores in 2026, with the focus remaining on premium shopping malls and outlets. At the same time, the Group will further consolidate the operating results of the regions that have transitioned and explore the possibility of rolling out the DTC model in other suitable regions to deepen market control and elevate consumer experience.In the new retail business, the Group will continue to advance its online channel layout, aiming to achieve over 15% growth in new retail sales in 2026. Through content-focused e-commerce and targeted live streaming, the Group seeks to reach more young customers and drive overall sales growth of 10%.The Group will steadily advance the business development of "MUNSINGWEAR", planning to continue expanding its physical store network in the Chinese Mainland and expanding its online sales channels to achieve online-offline synergy. In terms of international expansion, following its successful entry into the Malaysian market, the Group's company registration process in the Philippines has been completed, with business operations expected to officially commence in 2026, gradually refining its overseas channel layout.Mr. Wang Dong Xing, Chairman of China Lilang, concluded: “Looking ahead to 2026, the global geopolitical landscape remains complex and volatile, but the Chinese government continues to introduce policies and measures to promote consumption and expand domestic demand, providing support for the domestic market. Building upon the solid foundation established in 2025, China Lilang will focus on the development of its 'LILANZ' core collection and 'LESS IS MORE' smart casual collection, while deepening its new retail strategy and advancing multi-brand and overseas businesses, enabling it to advance towards a new stage of growth characterized by improvements in both quality and efficiency. It will also continue to drive R&D  innovation and strength its ESG initiatives, achieving concurrent business growth and sustainable development, striving to create stable and sustainable returns for shareholders."About China LilangChina Lilang is one of the leading PRC menswear enterprises. As an integrated fashion enterprise, the Group designs, sources and manufactures high-quality business and casual apparel for men and sells under brands of 'LILANZ' and 'LESS IS MORE' across an extensive distribution network, mainly in the PRC and overseas. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-16

中國利郎公佈二零二五年全年業績

香港, 2026年3月16日 - (亞太商訊 via SeaPRwire.com) - 中國利郎有限公司（「中國利郎」或「公司」，及其附屬公司，統稱「集團」；股份編號：1234）今天公佈其二零二五年全年業績。中國利郎主席兼非執行董事王冬星先生說：「二零二五年，中國內地服裝行業在宏觀經濟穩步復甦與消費市場溫和增長的背景下，整體保持基本穩定、承壓前行的發展態勢。男裝市場在消費升級大趨勢下呈現結構性分化，商務休閒、輕商務等中高端細分賽道成為增長核心動力，行業正加速從『數量競爭』邁向以『創新、品質與可持續發展』為核心的高質量競爭階段。中國利郎以差異化品牌矩陣深耕男裝市場，通過『利郎 LILANZ』主系列、『利郎 LESS IS MORE』輕商務系列及『萬星威 MUNSINGWEAR』運動線構建多元業務佈局，全方位滿足市場高品質、多元化的消費需求。同時，集團優化全渠道營銷佈局，強化線上線下協同營運，線上積極拓展新興平台、線下加速推動DTC模式，同步推進國際化佈局，多維度提升品牌影響力與營運效能。」年內，集團收入同比增長11.5%至人民幣40.7億元。其中，輕商務及其他系列收入大幅上升28.4%，主要得益於單店平均銷售額的大幅提升以及新零售渠道的突出表現。主系列收入增長6.0%，主要由於集團自去年起從分銷商收回分銷權轉以DTC模式經營後，於年內初步產生經營效益。毛利率為49.6%，同比上升1.9個百分點，主要因為直營銷售佔比上升提高平均單價，加上因收回分銷權產生的一次性收入扣除有所減少所致。權益股東應佔利潤為人民幣5.0億元（二零二四年：人民幣4.6億元），同比上升9.0%。股東應佔利潤率為12.3%，同比下降0.3個百分點。每股盈利同比上升9.0%至人民幣41.96分。董事會建議派發末期股息每股13港仙（二零二四年：9港仙）及特別末期股息每股3港仙（二零二四年：3港仙），連同已派發的中期股息，全年每股派息合共32港仙，維持穩定的派息比率。集團於年內以差異化品牌矩陣為核心戰略，深耕男裝市場。「利郎 LILANZ」主系列持續鞏固傳統男裝市場的競爭壁壘，透過優化產品結構、深化區域渠道佈局與滲透，進一步提升品牌在核心市場的認知度與市場份額。繼去年完成東北地區及江蘇省的分銷權回購轉制後，集團於年內加速推進渠道革新，再完成收回山東省及重慶市一級分銷商的經營權。針對年輕消費者的「利郎 LESS IS MORE」輕商務系列繼續以全直營模式經營，開店策略集中在消費者偏好的購物中心，以精準的門店形象提升消費體驗。截至二零二五年十二月底，主系列門店共2,446家，輕商務及其他系列門店371家，整體共2,817家門店，淨增加44家。年內，集團繼續集中在優質購物中心中的優越鋪位和奧特萊斯開店，通過最具品牌個性的裝修吸引顧客，提升銷售。於二零二五年十二月三十一日，購物中心店及奧特萊斯店增加至1,135家（二零二四年十二月三十一日：1,036家）。集團新零售業務完成戰略轉型，從過往的庫存清理渠道升級為主力新品銷售平台，年內收入錄得25%的顯著增長。集團持續深耕天貓、京東、抖音等成熟銷售平台的同時，拓展了拼多多、微信視頻號、得物等新興渠道，形成多元化線上銷售網絡。集團同時利用小紅書、微博等社交平台，持續輸出高品質內容，強化內容電商佈局，不僅深化了與消費者的情感聯結，更有效拓展了年輕客群，為新零售業務打開新的增長空間。「多品牌、國際化」發展戰略方面，高端高爾夫服飾品牌「萬星威 MUNSINGWEAR」作為集團多品牌戰略的關鍵佈局，上半年完成交易交割後，下半年在重慶及晉江等地開設首批實體門店，進一步豐富了集團的多元化品牌組合與高端產品線。而集團在馬來西亞開設首家門店的計劃順利落實，並於五月份順利試業。十一月於吉隆坡核心商圈Pavilion Bukit Jalil開設全球首家「未來商業（Future Retail）」概念旗艦店。於二零二五年十二月底已經開設4家門店，所有門店的順利營運，不僅完成了東南亞市場的初步佈局，更為集團後續輻射東南亞市場奠下重要基礎。年內，集團貫徹「簡約不簡單」的設計核心，深化全產業鏈自主研發，打造核心精品單品戰略，專注面料創新、工藝升級與標準制定，加強「技術賦能產品」的競爭優勢的同時更將自身技術積累轉化為全行業可參照的規範標準。面對機遇與挑戰並存的市場環境，中國利郎將保持審慎樂觀的態度，繼續深耕「多品牌、國際化」核心戰略，推進渠道改革、強化產品創新、提升運營效率，鞏固並提升集團於中國男裝行業的領先地位。集團計劃於二零二六年全年淨增加約50至100家門店，開店重點繼續聚焦於優質購物中心及奧特萊斯。同時，集團將進一步鞏固已轉型區域的經營成果，並探索在更多合適區域推廣DTC模式，以強化市場控制力、提升消費體驗。新零售業務方面，集團將持續推進線上渠道佈局，目標二零二六年實現新零售銷售額增長15%以上，並通過內容電商與精準直播觸達更多年輕客群，帶動整體銷售實現10%增長。集團將穩步推進「萬星威 MUNSINGWEAR」的業務發展，計劃在中國內地繼續拓展實體門店網絡，並拓展線上銷售渠道，實現線上線下聯動。國際化拓展方面，繼馬來西亞市場後，集團在菲律賓的公司註冊程序已完成，預計於二零二六年內正式開展業務，逐步完善海外渠道佈局。王冬星主席總結說：「展望二零二六年，全球地緣政治格局依然複雜多變，但中國政府持續推出促進消費、擴大內需的政策措施，為國內市場提供支撐。中國利郎將立足於二零二五年所奠定的穩健基礎，在聚焦『利郎 LILANZ』主系列及『利郎LESS IS MORE』輕商務發展的同時，深化新零售戰略，推進多品牌及海外業務，從而向質量與效率雙升的高階增長階段邁進，並將繼續透過研發創新，持續加強 ESG 建設，實現業務增長與可持續發展並行，致力為股東創造穩健及可持續的回報。」關於中國利郎中國利郎是中國領先的男裝企業之一。作為一家綜合時裝企業，集團設計、採購、生產並以品牌「利郎LILANZ」及「利郎LESS IS MORE」銷售優質男士商務及休閒服裝。其產品主要於中國及海外的廣闊零售及分銷網絡銷售。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-16

Accelerated Technology Commercialization Drives High-Growth Performance, Qunabox Group Leads the AI Interactive Marketing Track

HONG KONG, Mar 16, 2026 - (ACN Newswire via SeaPRwire.com) – As the integration of artificial intelligence technology with physical consumption scenarios enters a deeper stage, a dual revolution in business efficiency and consumer experience is unfolding. As a leader in China’s AI interactive marketing services sector, Qunabox Group (00917.HK) has achieved both rapid performance growth and a turnaround to profitability by leveraging its innovative business model of "technology middleware platform + multi-business synergy + global scenario deployment", setting a new benchmark for the digital transformation of the industry.AI-Powered Marketing Services, Building a Dual-Engine Model of "Technology + Data"At the core of Qunabox Group’s business model is the creation of a technology-driven, end-to-end value closed loop that upgrades AI from a single functional tool to a core engine embedded throughout the entire consumer journey. Marketing services, as the Group’s core business segment, has developed a dual-engine model of "standardization + value-added services", which continuously optimizes revenue quality and gross profit structure.In terms of service model, the Group has deeply covered key consumer sectors such as food and beverages, daily necessities, new energy vehicles and household appliances. With a high-quality, stable and diversified brand customer base as its foundation, the Group keeps deepening cooperation with major clients by expanding service scenarios and optimizing product portfolio, thus achieving simultaneous growth in both the number of clients and the value generated per client.In terms of product innovation, the Group takes technological R&D as the key driver, enabling AI to act as the "execution agent" throughout the end-to-end marketing value chain. The upgraded AI digital human shopping assistant, equipped with cross-sensory intent recognition and high-precision 3D modeling, delivers precise personalized recommendations and elevates user experience. The newly launched AI holographic marketing cabinet creates immersive display scenarios for high-intelligence products, restructuring the interaction mode of offline marketing. Meanwhile, the AI Agent marketing workstation enables closed-loop management across the entire process from content planning to performance tracking, raising marketing execution efficiency and precision to a new level.In the meantime, the implementation of the AIGC marketing resource library and the marketing selling points database for beverages and snack foods has made data value the core support for marketing decision-making, forming a new marketing service model driven by the dual wheels of "technology + data" and further consolidating the Group’s leading position in the field of AI interactive marketing.Global Layout in Innovative Tracks, R&D Innovation to Build Solid BarriersLifestyle and innovative businesses have injected long-term growth momentum into the Group’s business model. Focusing on "AI + Lifestyle", the Group has proactively explored emerging markets, with key focus on the Middle East, Southeast Asia and Australia where the demand for high-quality technology-enabled experiential consumption is robust. An overseas business department has been established to achieve end-to-end localized operation and management. At present, the AI indoor entertainment space has completed preliminary preparation and successfully obtained relevant business licenses in Dubai and Singapore.From the validation of localized models to the integration of software and hardware systems, and from the building of professional teams to the development of content ecosystem, the Group has realized cross-cultural and multilingual adaptation of its AI technologies through refined operation and management. This has allowed its "AI + consumption scenarios" business model to expand beyond domestic markets, providing innovative solutions for the upgrading of global consumer markets.In addition, other service businesses including IT system development leverage the Group’s technological reserves and first-mover advantages in AI applications to undertake technology development demands from industrial clients. These businesses have become an important extension of the commercialization of the Group’s technological capabilities, further enriching the Group’s revenue structure.In building technological barriers, Qunabox Group deeply integrates R&D innovation with intellectual property protection. The number of software copyrights registered in China and patents held by the Group has increased to 173 and 22 respectively, with an additional 133 patents currently under application, making technological innovation a solid guarantee for the sustainable development of the Group’s business model.At present, the integration of artificial intelligence and physical consumption is entering a phase of accelerated large-scale implementation. With its business model centered on "AI + Consumption Scenarios", Qunabox Group has not only achieved high-quality development for itself, but also reshaped the value creation model of the consumer industry.Looking ahead, Qunabox Group will continue to deepen its technological advantages and service capabilities, advance strategic industrial mergers and acquisitions, and optimize its AI-powered experiential consumption business model. By leveraging the synergy of new technologies, new scenarios and new markets, the Group aims to build a cross-regional, end-to-end AI lifestyle platform. It will keep driving industry innovation and progress, creating commercial value for brand clients, delivering new experiences for consumers, and generating long-term value for shareholders and society. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-16

富衛集團2025年全年業績創新高 實現盈利增長及資本與現金流創造能力提升

香港, 2026年3月16日 - (亞太商訊 via SeaPRwire.com) - 富衛集團有限公司（「富衛集團」或「富衛」）今日公布截至2025年12月31日的年度業績，是在香港上市後的首份全年業績。- 新增業務銷售額按年化新保費計算較2024年上升25% 至24.46億美元。新業務合約服務邊際為14.76億美元，按年增長18%。- 稅後營運利潤增長5%，達4.99億美元。香港特別行政區和澳門特別行政區、泰國和柬埔寨、日本以及新興市場四個地區業務分部皆為集團帶來正面貢獻。- 淨利潤達1.66億美元，自《國際財務報告會計準則》第17號實施後，連續第二年創新高。截至2025年12月31日，富衛集團實現正營運現金流。槓桿比率降至21.3%，接近富衛訂立的15%至20%的目標範圍。- 創造股東價值的重要指標大幅提升，綜合有形權益較2024年12月31日上升18%至87.2億美元；集團內涵價值按年增長19%至68.5億美元。償付能力比率保持穩健，達265%^。- 2025年12月，富衛集團獲納入恒生綜合指數，並被列入滬深港通的合資格股份名單，透過該機制，內地投資者可經由上海及深圳證券交易所以南向交易安排投資香港市場。2026年2月，富衛集團亦獲納入MSCI香港小型股指數。富衛集團行政總裁兼執行董事黃清風表示：「2025 年對富衛集團而言意義非凡。我們成功推行以客為先的策略，並憑藉數碼化營運模式，創下破紀錄的財務業績。我們於2025年7月成功完成首次公開招股，正式成為上市公司，達成了我們長期以來的目標，使富衛得以全面進入資本市場，為未來的發展和增長奠定穩固的基礎。」富衛集團2025年的強勁業績主要由其10個亞洲市場中大部分市場的有機增長所帶動，其中香港特別行政區及澳門特別行政區分部的表現最為突出。日本分部亦錄得穩健表現，在成功的保障業務基礎上，開始拓展退休及儲蓄領域，並推出首款日圓整付保費年金產品。富衛是泰國的市場領導者，儘管2025年業績受利率下行環境影響，以及2024年退出承保企業醫療新業務，泰國分部仍保持穩健地位，為未來優質新業務增長奠定堅實基礎。新興市場分部（涵蓋富衛集團東南亞其餘五個市場）錄得卓越增長，受惠於該地區長期的人口結構、財富累積及數碼化採用趨勢。黃清風補充道：「踏入2026 年，我們將堅定不移地執行既定策略，着眼未來發展，秉持以客為先的理念，深耕高速增長的亞洲市場，並持續聚焦長期可持續發展及盈利能力。」關於富衛集團富衛集團（香港聯合交易所上市代號：1828）為泛亞洲人壽及健康保險公司，服務超過3,800萬名客戶，業務遍及亞洲十個市場，包括印尼人民銀行人壽保險（BRI Life）。富衛秉持以客為先的方針及科技賦能的模式，致力為客戶帶來創新定位、簡單易明的產品和簡單的保險體驗。自2013年成立以來，富衛於部分全球發展最迅速的保險市場營運業務，專注為大眾創造保險新體驗。富衛集團在香港聯合交易所有限公司主板上市，股份代號為1828。如欲了解更多資訊，請瀏覽www.fwd.comFor media inquiries, please contact: groupcommunications@fwd.comSource: FWD Group Holdings Limited所有業績數據均截至 2025年12月31日並與2024年同期比較。集團當地資本總和法覆蓋率、集團內涵價值、綜合有形權益為2025年12月之結餘/比率和增長率。增長率按固定匯率計算，除非另有說明。稅後營運利潤/（虧損）（非國際財務報告會計準則計量指標）、淨利潤/（虧損）及綜合有形權益外，其他數據均未經審計師審核。稅後營運利潤及稅後淨利潤為公司權益持有人應佔部分，並已扣除非控股權益。新增業務銷售以年化新保費100%及整付保費10%組合計算。綜合有形權益按本公司股東應佔本集團權益總額加合約服務邊際結餘（扣除稅項及非控股權益），減無形資產（扣除非控股權益）計算。*按實際匯率計算^按訂明資本要求基準計算 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-16

AdsDrama Launches Short-Drama Marketing Ecosystem Launch in the Dominican Republic, Paving the Way for Digital Content Innovation

Santo Domingo, Dominican Republic, Mar 14, 2026 - (ACN Newswire via SeaPRwire.com) - In a strategic move to tap into the booming global short-drama market, AdsDrama LTD, an international digital content marketing company registered in Denver with $50 million in capital, has officially launched its tailored short-drama marketing ecosystem in the Dominican Republic. This event marks the company’s key step in expanding its global footprint, aiming to bridge the local content supply gap and build a sustainable digital entertainment model that combines its core strengths in advertising technology and community-driven growth.Short dramas — dozens of 1–3 minute episodes with fast-paced, emotional storytelling—are booming globally, fitting today's fragmented viewing habits. AdsDrama LTD, an international digital content marketing firm, is building a short-drama marketing ecosystem in the Dominican Republic, combining ad technology and community-driven strategies for sustainability.Short Dramas: The Next Digital Entertainment Growth EngineGlobal entertainment has shifted from long-form to short-form content, with short dramas offering advantages: 1–3 minute episodes, engaging storylines, mobile optimization, and higher monetization. The "free viewing + paid unlocking" model effectively retains audiences and generates revenue, fostering a full ecosystem of production, marketing, and commercialization.AdsDrama: Focused on Short-Drama MarketingRegistered in Denver with $50 million capital, AdsDrama's mission is a global short-drama marketing ecosystem integrating ad technology, distribution, data-driven strategies, and community promotion. Its core businesses include short-drama marketing, ad services, commercial operations, custom production, and IP incubation. Operating via "global technology + local operations," it adapts global expertise to local markets.Digital Advertising: The Growth EngineEffective distribution is key for short dramas. AdsDrama promotes content across social media, short-video platforms, portals, and search channels, optimizing campaigns via data analytics. Revenue streams include advertising, paid content, brand partnerships, and IP commercialization—forming the industry's financial foundation.Community-Driven "Co-Builder" ModelAdsDrama's "co-builder ecosystem" invites local participants to share content, provide market feedback, and expand reach. In return, co-builders get marketing materials, data access, and training—leveraging community trust, which outweighs algorithmic traffic in Latin America.User Experience & VIP StructureNew users get a free trial (RD$25–RD$60) to learn the platform's workflow and revenue model. For deep engagement, VIP levels (e.g., VIP3: RD$16,200 participation, daily returns of RD$270–RD$648 for 730 days) offer tiered benefits, with automatic revenue calculation and principal return options post-cooperation.Why the Dominican Republic?The country is a key market due to its young population (high digital entertainment demand), widespread mobile internet usage, and a gap in professionally produced short dramas—creating ideal conditions for ecosystem development.Three-Phase Development StrategyAdsDrama's 3-year plan: Phase 1 (1–6 months): Launch flagship dramas, build user communities, optimize marketing; Phase 2 (7–18 months): Expand promotion, improve operations, diversify revenue; Phase 3 (19–36 months): Open to independent creators, build a comprehensive ecosystem, and expand to the Caribbean and Latin America.The Future of the Digital Content EcosystemAs mobile internet continues to evolve, the digital entertainment industry is undergoing constant transformation.Short videos changed how audiences consume media. Short dramas may represent the next stage of this evolution - combining storytelling, advertising, and digital commerce in a single content format.Companies like AdsDrama LTD believe that the future of digital content will rely on the integration of multiple elements:creative storytellingtechnology infrastructuredata-driven marketingcommunity-based promotionIn this ecosystem:creators focus on producing contentplatforms provide technology and marketing toolscommunities help amplify distributionTogether, these elements form a sustainable and scalable digital content economy.Short dramas represent the next evolution of digital entertainment, integrating storytelling, advertising, and commerce. AdsDrama's focus on infrastructure, community, and data will drive the industry's growth, with the Dominican Republic and Latin America at the forefront of this transformation.Media contactBrand: AdsDrama LTDContact: Media teamWebsite: https://www.adsdrama.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-13

General MRO Aerospace 取得中國民航局認證，拓展全球維修能力

佛羅里達州邁阿密, 2026年3月13日 - (亞太商訊 via SeaPRwire.com) - General MRO Aerospace（GMA）今日宣布，已正式獲得中國民用航空局（CAAC）的認證，授權該公司為中國註冊飛機的部件提供維修、保養及大修（MRO）服務。此項認證標誌著 General MRO Aerospace 國際發展戰略的重要里程碑，並進一步印證了該公司對最高安全標準、品質及法規遵循的承諾。「取得 CAAC 認證是 General MRO Aerospace 持續拓展全球業務版圖的重要一步，」General MRO Aerospace 總裁 Jonathan Cornell 表示。「這項批准彰顯了我們品質體系的實力、技術專長，以及對支持全球航空公司與 MRO 合作夥伴的承諾。」獲得民航局（CAAC）批准後，GMA 得以依照中國航空監管要求，為各類飛機組件提供維修與大修服務。認證過程包含對該公司設施、品質管理系統、技術程序及法規遵循計畫的全面審核。General MRO Aerospace 目前已遵循 FAA Part 145、EASA、CAA 及 CAAT 品質標準營運，此次新增的 CAAC 認證將使該公司能更完善地服務亞太航空市場中的營運商、租賃商及維修服務供應商。「隨著全球對高品質部件維修服務的需求日益增長，這項認證強化了我們支援在中國及整個地區營運客戶的能力，」康奈爾補充道。「我們期待與中國航空公司及航空組織建立堅實的合作夥伴關係。」General MRO Aerospace 專精於複雜飛機部件的維修與大修，憑藉可靠的週轉時間、卓越的技術實力及以客戶為中心的服務，為全球商用及貨運營運商提供支援。關於 General MRO AerospaceGeneral MRO Aerospace 是一家總部位於美國、通過 AS9110 及 ISO 9001 認證的航空維修、保養與大修服務供應商，專門為全球商用飛機營運商提供部件維修與支援服務。憑藉FAA Part 145、EASA、CAA、CAAT及CAAC認證，該公司為全球航空公司、租賃公司及MRO合作夥伴提供高品質的技術解決方案、反應迅速的客戶服務以及可靠的維修週期。媒體聯絡人Michelle Torres行銷專員General MRO AerospaceMtorres@GeneralMROAerospace.com www.GeneralMROAerospace.com 消息來源：General MRO Aerospace Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-13

General MRO Aerospace Achieves CAAC Certification, Expanding Global Maintenance Capabilities

MIAMI, FL, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) - General MRO Aerospace (GMA) today announced that it has officially received certification from the Civil Aviation Administration of China (CAAC), authorizing the company to perform maintenance, repair, and overhaul (MRO) services for components on Chinese-registered aircraft.The certification marks a significant milestone in General MRO Aerospace's international growth strategy and further validates the company's commitment to the highest standards of safety, quality, and regulatory compliance."Achieving CAAC certification is an important step forward for General MRO Aerospace as we continue to expand our global footprint," said Jonathan Cornell, President of General MRO Aerospace. "This approval demonstrates the strength of our quality systems, our technical expertise, and our commitment to supporting Airline and MRO partners worldwide."The CAAC approval allows GMA to provide repair and overhaul services for a range of aircraft components in accordance with Chinese aviation regulatory requirements. The certification process included a comprehensive audit of the company's facilities, quality management system, technical procedures, and regulatory compliance programs.General MRO Aerospace already operates under FAA Part 145, EASA, CAA, and CAAT quality standards, and the addition of CAAC certification enables the company to better serve operators, lessors, and maintenance providers across the Asia-Pacific aviation market."With increasing global demand for high-quality component repair services, this certification strengthens our ability to support customers operating in China and throughout the region," Cornell added. "We look forward to building strong partnerships with Chinese airlines and aviation organizations."General MRO Aerospace specializes in the repair and overhaul of complex aircraft components, supporting commercial and cargo operators worldwide with reliable turnaround times, technical excellence, and customer-focused service.About General MRO AerospaceGeneral MRO Aerospace is an AS9110 and ISO 9001 accredited U.S.-based aviation maintenance, repair, and overhaul provider specializing in component repair and support services for commercial aircraft operators worldwide. Operating under FAA Part 145, EASA, CAA, CAAT, and CAAC certification, the company delivers high-quality technical solutions, responsive customer service, and dependable turnaround times to airlines, leasing companies, and MRO partners around the globe.Media ContactMichelle TorresMarketing SpecialistGeneral MRO AerospaceMtorres@GeneralMROAerospace.comwww.GeneralMROAerospace.comSOURCE: General MRO Aerospace Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-13

CMS (867.HK/8A8.SG) : New Drug for Renal Anaemia Desidustat Tablets Approved in China

SHENZHEN, CHINA, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that on 13 March 2026, new drug for renal anaemia Desidustat Tablets (the “Product”) has been approved for marketing in China by the National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a novel, oral HypoxiaInducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients.The approval of Desidustat Tablets will further strengthen the Group’s overall layout in the field of nephrology, and synergize with the marketed innovative drug Velphoro (Sucroferric Oxyhydroxide Chewable Tablets, indicated for CKD hyperphosphatemia). Through the efficient linkage of nephrology expert resources and channel networks, the Group is expected to rapidly promote the large-scale clinical application of Desidustat Tablets, providing differentiated treatment options for Chinese CKD patients with renal anaemia and making a positive contribution to the Group’s performance.More information about Desidustat Tablets and Renal AnaemiaAs a novel oral HIF-PHI, the Product’s mechanism of action promotes erythropoiesis through increasing endogenous erythropoietin, improving iron availability and reducing hepcidin. Its China Phase III clinical trial has demonstrated positive results. The primary endpoint of the haemoglobin (Hb) mean change from baseline to Week 7-9 has indicated that, Desidustat is more effective than placebo in increasing Hb level. Results from the extension study demonstrate that the Product can maintain Hb level within the target range over the long term with acceptable safety. In addition, the Product significantly reduces hepcidin levels and ameliorates iron metabolism disorders.There is still a large unmet need in the treatment of anaemia in CKD patients in China. It is estimated that there are more than 120 million CKD patients in China[1]. Anaemia is one of the frequent complications of CKD, which exhibits a progressively increasing incidence with disease progression. A survey in China showed that the prevalences of anaemia in patients at CKD stage 1 to 5 were 22.0%, 37.0%, 45.4%, 85.1%, and 98.2%, respectively[2]. The target-achieving rate (the Hb level reaching the target value (110~120g / L)) has increased to 51.5% for haemodialysis CKD patients with anaemia[3], but is still only 8.2% for anaemia patients in non-dialysis CKD[4]. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia.Desidustat Tablets have been approved for marketing in India.CMS INTERNATIONAL DEVELOPMENT AND MANAGEMENT LIMITED, a wholly-owned subsidiary of the Group, obtained an exclusive license for the Product from Zydus Lifesciences Limited (earlier known as Cadila Healthcare Limited) pursuant to a License Agreement with an effective date of 20 January 2020.The Group adheres to its core strategy of “innovation-driven”, having established a tiered and multi-dimensional innovation product portfolio with abundant reserves: 7 new drugs have been approved for marketing, 6 are currently under marketing review, and nearly 20 projects are about to initiate or are progressing through clinical trials. Through a dual-engine innovation approach combining collaborative development and in-house R&D, the Group continuously enriches its innovative pipeline centered on first-in-class (FIC) and best-in-class (BIC) products, efficiently advancing clinical development and commercialization. Moving forward, CMS will remain clinical needs-driven to deliver more quality pharmaceutical solutions, steadfastly advancing toward the goal of becoming a specialty-focused, innovation-excellent multinational pharmaceutical enterprise.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference1. ZhangL, WangF, WangL, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. DOI: 10.1016/S0140-6736(12)60033-62. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2014 Revised Edition)[J]. Chinese Journal of Nephrology, 2014, 30(9): 712-716. DOI: 10.3760/cma.j.issn.1001-7097.2014.09.0153. 19th CSN Critical Care & Blood Purification Congress, Chinese Medical Association (July 2-5, 2025)4. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2018 Revised Edition)[J]. Chinese Journal of Nephrology, 2018, 34(11): 860-866. DOI: 10.3760/cma.j.issn.1001-7097.2018.11.012CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-13

CITIC Resources Deepens Dual-Engine Strategy of ‘Investment + Trading’, Continues to Promote High-Quality Development

HONG KONG, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) – CITIC Resources Holdings Limited (hereinafter referred to as CITIC Resources or the Company, or the Group when its subsidiaries are included; Stock Code: 1205.HK) has announced its annual results for the year ended 31 December 2025 (the “Year”). During the Year, the Group actively responded to the complex international environment and cyclical industry pressures. Systematically advancing initiatives in “upstream asset deployment, expansion of trading business, and enhancement of production and operations”, the Group deepened its dual-engine development model of “investment + trading”, stabilised its core operations, cultivated a second growth curve, and demonstrated robust operational and developmental resilience.As a key growth driver for the Group, the oil and gas trading business within the import and export segment expanded steadily during the Year, achieving a significant milestone with a trading volume exceeding 20.0 million barrels and revenue reaching approximately HK$11.34 billion. Meanwhile, the Group broke the long-standing monopoly of the sales channel of crude oil, enhancing the market value of its oil and gas properties. In the non-oil-and-gas business, the Group consistently prioritises refined and proactive management of its equity investments as a core task and actively conveyed its philosophy of improving quality and enhancing efficiency to the operators. Notably, the value of shares held in Aloca Corporation (“Aloca”) increased by approximately 46.3% during the Year. On the oil and gas front, focusing on refined reservoir management and continuous scientific research breakthroughs, the Group achieved stable production and increased reserves. It comprehensively deepened lean management throughout the production process, coupled with the implementation of cost-reduction and efficiency-enhancement measures, propelled continuous improvements in management standards and operational efficiency across all phases of oil and gas projects from exploration, development to production.During the Year, the Group achieved revenue of approximately HK$14.96 billion (2024: approximately HK$9.50 billion), representing a year-on-year increase of approximately 57.6%. Impacted by factors such as a decline in the average selling price of crude oil and coal, and higher raw material costs, profit attributable to ordinary shareholders of the Company amounted to approximately HK$0.17 billion (2024: HK$0.57 billion). Despite that, all of the Group’s segments recorded profits for the Year and the Group continued to maintain a strong financial position with cash and deposits of approximately HK$3.52 billion as at 31 December 2025 (31 December 2024: HK$2.03 billion). As at 31 December 2025, the Group had total assets of approximately HK$14.61 billion, and net assets attributable to ordinary shareholders of the Company of approximately HK$8.79 billion. The gearing ratio and interest-bearing debt ratio were approximately 38.8% and 23.5% respectively, with a return on equity (annualised) of approximately 2.0%.As part of its efforts to optimise its asset structure, the Group disposed of shares in Alcoa in January and March 2026, totalling approximately 2.17% of Alcoa’s total issued shares[1]. By seizing the opportunity to monetise its investment at a high valuation, the Group continues to create greater value for its shareholders.Mr. Hao Weibao, Executive Director, Chairman and Chief Executive Officer of CITIC Resources, said: “Looking ahead to 2026, the Group will focus on key areas such as the development, production and trading of oil and gas, as well as investments in the aluminum industry chain, deepen synergies among trading, investment and production management, and continue to implement the business strategy of consolidating the existing core business and pursuing dual-engine expansion through ‘investment + trading’.To consolidate our existing principal business, the Group will continue to enhance lean production and operational management to increase reserves and output, while steadily expanding production and sales scale. The Group will also intensify the introduction and application of new processes and technologies, leveraging technological innovation to empower high-quality development of our core businesses and reinforce our core growth foundation.On the dual-engine driver of ‘investment + trading’ expansion front, the Group will continue to track and position in high-quality oil and gas assets and the aluminium-centric key metals industry chain. Trading operations and investment projects will be deeply integrated: the investment arm will secure equity resources, while the trading arm will achieve market-oriented sales. This approach will also enhance our market sensitivity, enabling us to identify and acquire high-quality upstream resources and assets, thereby creating a virtuous cycle in which ‘investment acquires resources and trading converts value’. The Group is committed to implementing these development strategies and will continue to deliver long-term and stable returns to our shareholders.”[1]Details regarding the disposal were disclosed in the announcements and circular dated 16 January, 6 February, and 5 March.For details of CITIC Resources’ 2025 annual results, please refer to the Group’s annual results announcement on the Hong Kong Stock Exchange and the Group’s website.About CITIC Resources Holdings Limited (Stock Code: 1205.HK)CITIC Resources Holdings Limited has been listed on the Hong Kong Stock Exchange since 1997. Principal activities of CITIC Resources include the exploration, development and production of oil and coal, investments in bauxite mining, alumina refinery, aluminium smelting and oil and gas trading. CITIC Limited is the largest shareholder with about 59.5% interest in CITIC Resources. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-13

中信資源深化「投資+貿易」雙輪戰略 持續驅動高質量發展 推進「上游資產布局、貿易業務拓展、生產運營提質」

香港, 2026年3月13日 - (亞太商訊 via SeaPRwire.com) - 中信資源控股有限公司（「中信資源」或「公司」，連同其附屬公司統稱為「集團」；股份代號：1205.HK）公布截至2025年12月31日止年度（「年内」）之全年業績。年內集團積極應對複雜國際市場環境及行業週期性波動壓力，系統推進「上游資產布局、貿易業務拓展、生產運營提質」工作，深化「投資+貿易」雙輪驅動發展模式，穩固經營基本盤，培育第二增長曲線，彰顯了強大的經營和發展韌性。作為集團主要的增長引擎之一，進出口業務板塊中的油氣貿易業務年內穩步拓展，貿易量超2,000萬桶，實現貿易收入約113.4億港元，達成重大里程碑。集團同時打破權益油銷售多年被壟斷局面，提升權益油市場價值。非油業務方面，集團始終將參股項目的精細化、主動化管理作為核心工作，向作業方傳導提質增效理念，其中所持有的美國鋁業公司（「美國鋁業」）股份價值年內增長46.3%。油氣業務方面，集團以精細化油藏管理與持續科研攻關為核心，實現穩產增儲；全面深化生產過程的精益管理，落實降本增效舉措，推動油氣項目在勘探、開發及生產各環節的管理水平和運營效益持續提升。年內，集團實現營業收入約149.6億港元（2024年：約95.0億港元），同比增長約57.6%。受原油及煤炭的平均售價下降、原材料成本上升等因素影響，本公司普通股股東應佔溢利約1.7億港元（2024年：約5.7億港元）。儘管如此，集團全部分類於本年度錄得溢利，且於2025年12月31日繼續維持穩健的財務狀況，現金及存款約為35.2億港元（2024年12月31日：20.3億港元）。截至2025年12月31日，集團總資產146.1億港元，歸母淨資產約87.9億港元，資產負債率約38.8%，有息負債率約23.5%，淨資產收益率約2.0%。作為優化資產結構的舉措之一，集團於2026年1月及3月先後減持美國鋁業股份，累計出售相當於其已發行股份總數約2.17%。集團精準把握高位變現的時機，持續為股東創造更大價值[1]。中信資源執行董事、主席兼行政總裁郝維寶先生表示：「展望2026年，集團將聚焦油氣開發生產與貿易、鋁產業鏈投資等關鍵領域，深化貿易、投資與生產運營協同，持續貫徹『夯實存量主業、「投資+貿易」雙輪拓展』的經營策略。夯實存量主業方面，集團將持續深化精益生產運營管理，實現增儲上產，穩步擴大產銷規模；同時加大新工藝、新技術引進與應用力度，以科技創新賦能主業高質量發展，築牢核心發展根基；『投資+貿易』雙輪拓展方面，持續跟蹤和佈局優質油氣資產及以鋁為核心的關鍵金屬產業鏈，貿易業務與投資項目形成深度聯動，投資端獲取權益資源，貿易端實現市場化銷售，同時形成市場觸角，識別並獲取位於產業鏈上游的優質資源資產，形成『投資獲取資源，貿易轉化價值』的良性循環。集團將致力落實此等發展戰略，持續為廣大股東創造長期穩定的價值回報。」[1]出售事項的相關詳情可見於1月16日、2月6日及3月5日刊出的公告及通函。有關中信資源2025年全年業績的詳情，請參考集團在香港聯交所及其網站的全年業績公告。關於中信資源控股有限公司（股份代號：1205.HK）中信資源控股有限公司自1997年起，在香港聯合交易所上市。中信資源的主要業務包括石油和煤的勘探、開發和生產，於鋁土礦開採、氧化鋁冶煉和電解鋁領域的投資及油氣貿易。中國中信股份有限公司持有中信資源約59.5%的股權，為中信資源最大股東。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-13

康哲藥業：腎性貧血新藥德昔度司他片中國獲批上市

深圳, 2026年3月13日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司(867.HK/8A8.SG)（「康哲藥業」）欣然宣佈，腎性貧血新藥德昔度司他片（原名：德度司他片）（「產品」）上市許可申請已於2026年3月13日獲得中國國家藥品監督管理局（NMPA）批准。產品為一種創新型口服低氧誘導因子-脯氨醯羥化酶抑制劑（HIF-PHI），適用於非透析的成人慢性腎臟病（CKD）患者的貧血治療。德昔度司他片獲批上市，將進一步強化康哲藥業在腎病專科領域的整體佈局，並與處於商業化階段的創新藥維福瑞（蔗糖羥基氧化鐵咀嚼片，用於CKD高磷血症）協同增效。通過腎內科專家資源與渠道網絡的高效聯動，康哲藥業有望快速推動德昔度司他片的規模化臨床應用，為中國CKD腎性貧血患者提供差異化的治療選擇，為集團業績帶來積極貢獻。關於德昔度司他片和腎性貧血的更多信息作為一種創新型口服HIF-PHI，產品作用機制為通過增加內源性促紅細胞生成素的生成、改善鐵的利用率和降低鐵調素的水平來促進紅細胞生成。其中國III期臨床試驗取得了積極結果。主要研究終點血紅蛋白（Hb）水平（第7-9周Hb平均值相對於基線的變化）結果顯示，試驗組優於安慰劑組。擴展期研究結果顯示，產品可使Hb水平長期維持在達標水平，且安全性良好。此外，產品還可以顯著降低鐵調素水平，糾正鐵代謝紊亂。中國CKD貧血治療領域仍存在顯著的未被滿足需求。據估計，中國有超過1.2億CKD患者[1]，貧血作為其常見併發症之一，發生率隨病程進展呈逐步升高趨勢。國內一項調研顯示，CKD1～5 期患者貧血患病率依次為：22.0%、37.0%、45.4%、85.1%和98.2%[2]。血液透析CKD貧血患者的治療達標率（Hb水平達到靶目標值（110～120 g/L））已提升至51.5%[3]，但對於非透析CKD貧血患者來說仍僅為8.2%[4]。產品採用口服給藥，有望提高患者的治療順應性，有望滿足CKD貧血領域未被滿足的治療需求。產品已在印度獲批上市。康哲藥業之全資附屬公司康哲國際發展管理有限公司通過生效日為2020年1月20日的《許可協議》從Zydus Lifesciences Limited（前稱為Cadila Healthcare Limited）處獲得產品的獨家許可權利。康哲藥業堅持 「創新驅動」 核心戰略，已構建起梯隊銜接、儲備充足的立體化創新產品矩陣：7款新藥獲批上市、6款正處於上市審評階段、近20個項目即將開展/正在推進臨床試驗。康哲藥業通過「合作開發+自主研發」雙輪驅動創新，持續豐富以全球首創（FIC）、同類最優（BIC）產品為核心的創新管線，高效推進臨床開發與商業化落地。未來，康哲藥業將繼續以臨床需求為導向，提供更多優質醫藥解決方案，堅定向專科聚焦、創新卓越的國際化醫藥企業邁進。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化，把控產品全生命週期管理的開放式平臺型企業，致力於提供有競爭力的產品和服務，滿足尚未滿足的醫療需求。康哲藥業專注於全球首創（FIC）及同類最優（BIC）的創新產品，並高效推進創新產品臨床研究開發和商業化進程，賦能科研成果向診療實踐的持續轉化，造福患者。康哲藥業聚焦專科領域，擁有被驗證的商業化能力，廣泛的渠道覆蓋和多疾病領域專家資源，核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展，以鞏固心腎代謝/消化/眼科/皮膚健康業務競爭力，帶來專科規模效率，其中皮膚健康業務（德鎂醫藥）已成為其細分領域的龍頭企業，並擬於聯交所獨立上市。同時，康哲藥業持續推動研產銷全產業鏈在東南亞及中東區域運營發展，以獲取新興市場的增量，助力集團實現高質量可持續發展。參考文獻/資料1.ZhangL, WangF, WangL, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. DOI: 10.1016/S0140-6736(12)60033-62.腎性貧血診斷與治療中國專家共識（2014修訂版）[J]. 中華腎臟病雜誌, 2014, 30(9): 712-716. DOI: 10.3760/cma.j.issn.1001-7097.2014.09.0153.中華醫學會腎臟病學分會第十九屆重症腎臟病與血液淨化大會（2025年7月2-5日）4.腎性貧血診斷與治療中國專家共識（2018修訂版）[J]. 中華腎臟病雜誌, 2018, 34(11): 860-866. DOI: 10.3760/cma.j.issn.1001-7097.2018.11.012康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣，非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療信息，請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請，不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制，但康哲藥業並無進行任何說明或保證、明述或暗示，或其他表述，對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述，該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證，存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測，康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-13

uSMART HK Expands to 12 Physical Service Centres in One Year, Accelerating “Online x Offline” O2O Community Finance Strategy

HONG KONG, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) – uSmart Securities Limited ("uSMART Securities/the Company") is pleased to announce the official opening of its ninth and tenth physical service centres in Tai Wai and Tuen Mun. Within just one year, uSMART Securities has expanded its Hong Kong service network to 12 physical service centres, surpassing industry benchmarks and actively implementing its "Online x Offline" (O2O) community finance strategy. This expansion solidifies its position as the “No.1 Hong Kong Funded Fintech Brokerage^” and further enhances brand influence.Promoting Accessible Community Financial ServicesThe Tuen Mun branch held a simple yet meaningful opening ceremony today, marking the official commencement of services and a new chapter in the Company's development. Mr. Neo Lee, Executive Director of uSMART Securities, stated: "The opening of the Tai Wai and Tuen Mun branches represent a crucial strategic move in our commitment to local communities and advancing community-oriented services. We focus not only on network coverage but also on connecting with the community, upholding our 'customer-centric' philosophy. By bridging the gap with residents, we are advancing toward our goal of 'seamless coverage across Hong Kong'."(From left to right: Business Development Manager of uSMART Securities, Executive Director of Research Department of uSMART Securities, Executive Director of uSMART Securities, Marketing Director of uSMART Securities and Business Development Director of uSMART Securities)(From left to right: Business Development Manager of uSMART Securities, Executive Director of Research Department of uSMART Securities, Executive Director of uSMART Securities, Marketing Director of uSMART Securities and Business Development Director of uSMART Securities)Comprehensive Coverage Across Hong Kong 18 DistrictsAiming to accelerate the goal of becoming "the Fintech brokerage with the most service centres in Hong Kong," uSMART Securities will open branches in core areas, Kai Tak and Mong Kok in the second quarter. The company is also actively exploring pop-up stores in shopping malls and participating in various exhibition booths. Through multi-channel engagement with customers across different districts, the company aims to refine its regional presence, enabling citizens across all 18 districts to easily access professional and personalized investment and wealth management services, seamlessly integrating financial experiences into daily life.Diversified Investment ProductsAt the opening ceremony, Neo revealed that uSMART Securities has recently obtained a futures trading license and is preparing to launch futures trading services by mid-year. Upon launch, clients will be able to trade futures, including index futures, commodity futures, and currency futures via the uSMART platform. This expansion provides investors with a more comprehensive range of investment products covering long-term, medium-term, and short-term investments, as well as low, medium, and high expected returns, catering to diverse client needs.Futures services will be fully integrated into the existing uSMART APP trading platform, allowing clients to trade US and Hong Kong stocks, futures, ETFs, funds, and discretionary investment products from a single APP. This enables diversified asset allocation, risk management, and wealth enhancement services, allowing clients to utilize capital efficiently and manage investment portfolios flexibly, truly achieving "one-stop wealth management with comprehensive asset allocation."Promoting Investment Education and Enhancing Client InteractionuSMART Securities is also committed to advancing investor education, regularly hosting various online and offline investment seminars and thematic events such as wine tastings and cocktail workshops. These initiatives deepen client engagement and relationships, enhancing customer retention and loyalty.Meanwhile, a new financial channel led by stock commentator and Executive Director of Research, Mr. Dickie Wong, will officially launch next Monday (March 16). Before the market opens and midday close on every Hong Kong stock trading day, a professional team will provide you with real-time analysis of market dynamics and investment opportunity. uSMART Securities aims to foster closer interaction, helping clients refine their practical skills, optimize investment decisions, and build a more comprehensive platform for learning and practice.Expanding Team SizeIn line with rapid business growth, uSMART Securities is actively advancing local talent recruitment and training. The company expects to increase its workforce by 30% over the next two years across areas including branch operations, product design, wealth management, compliance and risk control, and marketing operations. This expansion aims to enhance team scale and professional capabilities, driving steady business growth.Looking ahead, uSMART Securities will continue to optimize trading experiences and strengthen synergies between offline service points and community activities, further solidifying its leading position in financial technology. By combining innovative technology with community networks, the company strives to provide more convenient and personalized wealth management services for investors of all ages and experience levels, promoting the popularization and intelligent development of Hong Kong's financial ecosystem.^”No.1 Hong Kong Funded Fintech Brokerage" is based on TradeGo Cloud data, with uSMART Securities ranking first in monthly transaction volume among local Hong Kong-funded internet brokers for over a year as of February 2026.About uSMART:uSMART Securities is a leading Hong Kong Funded Fintech Brokerage founded in 2018. Over the past eight years, it has pioneered the fusion of technology and finance, offering stocks trading, asset management, and wealth management solutions. Its proprietary platforms, uSMART HK APP and uSMART SG APP, operated by uSMART Securities (Hong Kong) and uSMART Securities (Singapore) respectively. It supports investments in Hong Kong stocks, US stocks, A-shares (via Shanghai and Shenzhen Stock Connect), Singapore Stocks, Japan Stocks, UK Stocks, US options, ETFs, Funds, Bonds, Asset Management, Structured Notes, Futures, Crypto, Precious Metals, Gold, and forex. Furthermore, uSMART is equipped with a highly professional research and asset management team that offers asset management, wealth management, securities brokerage, institutional business, LPF services, and investment banking, dedicated to serving ultra-high-net-worth individuals and families, corporations, investment institutions, fund companies, and other brokerage firms with comprehensive asset management solutions.For details please visit: https://hk.usmartglobal.comFor any media queries, please contact:Carrie Wong9788 4665carriewong@usmart.hk Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-13

盈立證券一年拓展12個服務網點 全力深化「線上x線下」O2O社區金融佈局

香港, 2026年3月13日 - (亞太商訊 via SeaPRwire.com) - uSMART盈立證券有限公司（下稱「盈立證券」或「本公司」）欣然宣佈，第九及第十間實體服務中心正式進駐大圍及屯門，短短一年內，盈立證券全港服務網絡已增至12間服務中心，超越全行，積極實踐「線上 x 線下」（O2O）社區金融策略，鞏固港資科技券商No.1^地位，進一步擴大品牌影響力。推動社區金融服務普及化屯門分行今日舉行簡單而隆重的開幕典禮，標誌該分行正式投入服務，為本公司的發展里程寫下嶄新一頁。盈立證券執行董事李建翰先生 (Neo) 表示：「大圍及屯門分行的開業，是我們心繫本地社區，持續推動社區化服務的重要戰略性部署。我們不僅追求網絡覆蓋率，更重視與社區的連結，貫徹『以客為本』的理念，拉近與居民的距離，朝『全港無縫覆蓋』的目標邁進。」(左起︰盈立證券業務拓展經理林向尊先生、盈立證券研究部執行董事黃德几先生、盈立證券執行董事兼機構業務負責人李建翰先生、盈立證券香港市場部總監黃曉霖小姐及盈立證券業務拓展總監鄧永麟先生)(左起︰盈立證券業務拓展經理林向尊先生、盈立證券研究部執行董事黃德几先生、盈立證券執行董事兼機構業務負責人李建翰先生、盈立證券香港市場部總監黃曉霖小姐及盈立證券業務拓展總監鄧永麟先生)全港18區服務全覆蓋為加速實現『全港最多服務中心的科技券商』的目標，盈立證券將於第二季在核心地區 ─ 啟德及旺角開設分行，並積極物色商場期間限定店及參與各類展會攤位，希望透過多渠道接觸不同地區客戶，藉此進一步完善地區性佈置，讓全港18區市民皆可輕鬆獲取專業、個性化的投資理財服務，把金融體驗融入日常生活。」投資產品多元化Neo在開幕典禮上透露，盈立證券早前更取得期貨交易牌照，並正籌備於年中正式推出相關期貨交易業務。屆時客戶可透過uSMART平台進行期貨交易，涵蓋指數期貨、商品期貨及外匯期貨等，為投資者提供更全面的投資產品，長、中、短線投資以及低、中、高預期回報俱備，滿足不同客戶的需求。期貨業務將全面整合至現有的 uSMART APP交易平台，客戶可使用同一個APP買賣美港股、期貨、ETF、基金及全權委託投資產品等，即可享受多元資產配置、風險管理及財富增值服務，高效地運用資金，靈活地管理投資組合，真正實現「一站式理財．全方位佈局」。推動投資教育 強化客戶互動體驗盈立證券對推動投資者教育亦不遺餘力，定期舉辦不同類型的線上及線下的投資講座，及主題活動，如葡萄酒品鑑會及雞尾酒工作坊，深化與客戶的互動與關係，提升客戶黏度，增加客戶忠誠度。同時，由資深股評人兼研究部執行董事黃德几先生（Dickie）親自帶領的全新財經台，將於下周一（3月16日）強勢啟播，每個港股交易日的早上開市及中午收市前，由專業團隊為您即時剖析市場動態與投資機遇。盈立證券期望透過更緊密的互動，協助客戶精進實戰技巧、優化投資決策，打造更完善的學習與實踐平台。擴大團隊規模　配合業務高速發展，盈立證券正積極推進本地人才招募與培訓，預計未來兩年職位數量將增加30%，涵蓋前線分行、產品設計、財富管理、合規風控及市場營運等範疇，全面擴大團隊的規模及專業能力，推動業務穩健成長。 展望未來，盈立證券將持續優化交易體驗，並加強線下網點與社區活動的協同效應，進一步鞏固在金融科技領域的領先地位；同時結合創新科技與社區網絡，為不同年齡及資歷的投資者提供更便捷、更具溫度的理財服務，推動本地金融生態朝普及化及智能化發展。^「港資科技券商No.1」是取自捷利金融雲截至2026年2月為止連續超過一年數據， uSMART盈立證券為香港本地港資互聯網券商月成交總額排行第1。關於uSMART盈立證券：盈立證券 是一間領先科技港資券商，成立於2018年，8年來憑藉卓越的戰略規劃和創新能力，致力於將科技與金融深度融合，業務範圍涵蓋證券、資產管理、財富管理等領域，為全球投資者獨家研發了金融證券交易平台 uSMART HK APP和 uSMART SG APP，分別由盈立證券（香港）和盈立證券（新加坡）提供服務。集團APP 支持港股、美股、A股（滬深港通）、新加坡股票、日本股票、英國股票、美股期權、ETF、基金、債券、資管、結構化票據、期貨、加密貨幣、貴金屬、黃金和外匯等多元化的投資交易服務，此外更為超高淨值個人與家族、企業提供度身訂制服務，打造全方位綜合性資產管理解決方案。詳情可瀏覽 https://hk.usmartglobal.com傳媒查詢：黃曉霖 Carrie Wong9788 4665carriewong@usmart.hk Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-13

CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream (Lumirix(R)) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo

SHENZHEN, CHINA, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) - On 12 March 2026, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health, which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited) has its innovative prescription medicine ruxolitinib phosphate cream (Lumirix®) (the “Product”, marketed as Opzelura® in the U.S., Europe and Canada) recorded the initial prescriptions for vitiligo patients across 30 provincial-level regions. The prescriptions cover approximately a thousand influential public and private medical institutions in the field of skin health and disease management, including Huashan Hospital, Fudan University, Shanghai Skin Disease Hospital, Dermatology Hospital of Southern Medical University, Second People's Hospital of Chengdu, The First Bethune Hospital of Jilin University, The Second Xiangya Hospital of Central South University, United Family Healthcare Group, among others*. Meanwhile, the Product has become concurrently accessible via over 1,300 offline drugstores as well as JD.com e-commerce platform. *Hospital rankings are listed in no particular order.As the first topical JAK inhibitor approved in China for the treatment of vitiligo, ruxolitinib phosphate cream has officially launched its large-scale clinical application today, marking a breakthrough in China’s vitiligo treatment landscape and ushering in a new era of precision targeted therapy for vitiligo. Supported by safety and efficacy fully demonstrated in clinical studies, the Product is expected to bring new hope for repigmentation to millions of vitiligo patients.The rapid commercialization progress of ruxolitinib phosphate cream underscores strong product operation capabilities of CMS (including Dermavon), while also reflecting the robust supports from China’s regulatory reforms in accelerating patient access to clinically urgently needed innovative drugs. Benefiting from the integrated healthcare ecosystem of the Hainan Free Trade Port and the “Urgently Needed Imported Drugs for Clinical Use” policy, the Product initiated pilot clinical use in August 2023 at Boao Super Hospital within the Boao Lecheng International Medical Tourism Pilot Zone. Pilot usage subsequently expanded to designated medical institutions across the Guangdong–Hong Kong–Macao Greater Bay Area, Beijing-Tianjin region and other regions. In accordance with the relevant regulations of China’s real-world data application pilot project, as well as supported by the Hainan Provincial Medical Products Administration and the Administration of the Boao Lecheng International Medical Tourism Pilot Zone, the Product has accumulated real-world clinical data in China under pilot application, significantly accelerating its clinical, registration and approval timelines. The Product received its Drug Registration Certificate on January 30, 2026 (approval date: January 27, 2026).Following its approval, in less than 1.5 months (including the Chinese New Year holiday), the initial prescriptions for ruxolitinib phosphate cream have been issued across multiple regions and hospitals, reflecting the highly efficient collaboration and concerted efforts among CMS teams, regulatory authorities and business partners. With robust support from the cross-departmental coordination mechanism of the Beijing Daxing Airport Economic Zone Joint Administrative Committee, once import conditions were met, the Product completed customs clearance approval, sampling and related customs procedures within 24 hours, and obtained the drug testing report within 7 working days, representing efficient execution and acceleration for the innovative drugs in China. During this process, the Beijing Municipal Medical Products Administration proactively provided end-to-end policy guidance; the government service center has efficiently completed customs clearance filing; the Beijing Institute for Drug Control has conducted methodological pre-testing to accelerate timelines for innovative drug, and continuous worked during the Chinese Spring Festival; and Daxing Airport Customs provided specialized pre-guidance on declaration and swiftly completed customs review and release. Through parallel workflows and coordinated execution, all parties collectively pressed the “fast-forward button” for the Product’s commercialization, helping this urgently needed innovative therapy reach patients faster.As the Product enters the large-scale clinical application stage, it is expected to further strengthen Dermavon’s comprehensive dermatology solutions and brand value. Building on its leadership in skin health, Dermavon will continue to improve accessibility of ruxolitinib phosphate cream to benefit more vitiligo patients and steadfastly safeguard public skin health through innovation.About VitiligoVitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. The discolored areas usually get bigger with time and the condition could influence skin on any part of the patients’ body. Vitiligo usually affects the appearance of patients, especially on exposed areas such as the face and neck. According to a study that involved over 1,000 diagnosed vitiligo patients, over 45% of patients have facial involvement, and over 20% of patients have neck involvement[1].The obvious presence of white patches may make patients feel that their appearance has been compromised, which in turn materially affects their social life, and is associated with a significantly higher incidence of mental health disorders; accordingly, there is an urgent need for effective treatment options for vitiligo[2].It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[1]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. Ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance.More Information About Ruxolitinib Phosphate CreamRuxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is the first and only drug approved for the repigmentation of non-segmental vitiligo by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)[3,4]. In the U.S., the Product is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised adult and pediatric patients aged 2 years and older whose disease is not well controlled with topical prescription therapies, or when those therapies are not advisable. In Europe, ruxolitinib phosphate cream is approved for the topical treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. In China, besides vitiligo indication, the product’s NDA for the treatment of mild-to-moderate AD in adults and pediatric patients aged 2 years and older is also under regulatory review, which has been included in the Priority Review List and is expected to accelerate the Product’s AD review process for marketing approval.The Group, through the subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary).Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream (excluding territories in which exclusive rights have already been licensed), marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. China Insights Consultancy’s industrial report 2. Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis[J]. Journal of the European Academy of Dermatology and Venereology, 2018,32(8):1343-1351. DOI:10.1111/jdv.14739. 3. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream4. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurarCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-13

Guoquan Achieves Simultaneous Growth in Scale and Profitability, Core Operating Profit Increases by 48.2% in 2025

HONG KONG, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) – 12 March 2026, Guoquan Food (Shanghai) Co., Ltd. ("Guoquan" or the "Company"; stock code: 2517.HK), a leading one-stop home meal products brand in China, announced its annual results for the year ended 31 December 2025, which have been reviewed by the Audit Committee of the Board.Adhering to the strategic positioning of "community central kitchen" in 2025, the Company successfully established a holistic instant retail store network through a multi-channel, multi-scenario omni-channel layout and the deep integration of online and offline operating models. The Company continuously delved into consumers' demand, developed and iterated a diverse suite of product portfolios, deepened refined store operation and management, and strengthened the construction of a membership ecosystem, effectively enhancing store operational efficiency and market competitiveness. Concurrently, the Company continued to deepen its industrial layout and promote the integrated closed-loop construction of "production, supply and marketing", achieving stable development throughout the year.For the year ended 31 December 2025, the Company's revenue amounted to RMB7,810.0 million, representing a year-on-year increase of 20.7%. Gross profit reached RMB1,686.6 million, a year-on-year increase of 19.0%. Net profit was RMB453.9 million, a significant year-on-year increase of 88.2%. Core operating profit (adjusted for non-recurring items such as gains or losses on fair value changes on unlisted convertible redeemable preferred shares and donations for fire rescue in Tai Po, Hong Kong) was RMB460.7 million, representing a year-on-year increase of 48.2%. Basic and diluted earnings per share were RMB0.1630, a substantial year-on-year increase of 93.8%.Continuously Strengthening Omni-channel Instant Retail: Offline Expansion and Online Engagement Drive GrowthAs of 31 December 2025, the Company's total number of stores nationwide reached 11,566, a net increase of 1,416 stores from 10,150 as at the end of 2024, covering 31 provinces, autonomous regions and municipalities. In terms of regional store layout, the Company achieved a net increase of 1,004 township-level stores in 2025. Addressing the consumption characteristics and needs of township markets, the Company developed differentiated product structures and store displays, accurately aligning with consumer demands in lower-tier markets and further enhancing township market penetration. Concurrently, the Company continued to deploy smart retail scenarios in mid-to-high-tier markets, completing the intelligent and unmanned transformation and upgrade of over 3,000 retail stores in 2025, achieving synergistic development between lower-tier and mid-to-high-tier markets.To empower franchisees, facilitate their sales growth, and further expand consumer reach while offering a more flexible shopping experience, the Company continuously provides support and guidance to franchisees in core areas such as store operations and business development. Leveraging the Company's Guoquan APP, WeChat mini-program, third-party food delivery platforms and social commerce platforms (such as Douyin), a multi-level online sales network has been established. In 2025, the Company achieved over 9.41 billion impressions on platforms through its multi-level Douyin accounts matrix. Stores generated GMV of RMB1.49 billion via the Douyin channel, representing a year-on-year increase of 75.3%.Membership Ecosystem Continuously Improved; Product Portfolio Enhances in Scenarization and RichnessIn 2025, the operation of the Guoquan membership program yielded significant results, further releasing the value of the membership ecosystem. During the Reporting Period, the number of the Company's registered members reached approximately 64.9 million, a year-on-year increase of 57.1%, demonstrating rapid expansion of the membership base. The prepaid card business also achieved stable growth, with the value stored in prepaid cards amounting to approximately RMB1.2 billion during the Reporting Period, a year-on-year increase of 22.3%. This indicates continuously improving member stickiness and consumption contribution, forging a closer connection with consumers.Relying on its substantial membership base, the Company persistently pursues innovation in its product offerings, consistently upholding the business philosophy of providing consumers with "tasty, convenient and value-for-money" products. It continuously enriches its product portfolio and iterates new products to comprehensively meet consumers' diverse dining needs. As of 31 December 2025, the Company had introduced 282 new SKUs of hot pot and barbecue products. It created multiple scenarized meal suites such as the "Barbecue Camping Container Set", "Crayfish Feast Set", and "Six Popular Hot Pot Sets", achieving deep integration of products and consumption scenarios. Furthermore, the Company expanded its product categories within the drinks and beverage consumption scenario, launching products such as NFC fruit juices, craft beer, and flavored tea beverages. This continuously enhances the richness and diversification of the product matrix, further perfecting the one-stop meal products supply system.Deepening Industrial Layout; Strengthening Digitalized Supply Chain ControlGuoquan continues to promote the integrated closed-loop construction of "production, supply and marketing". Adopting a "one-product-one-factory" strategy, it further deepens the breadth and depth of its industrial layout, providing solid production capacity support for business development. As of 31 December 2025, the Company possessed seven food ingredient production plants, covering core categories such as condiments, meatballs, paste and aquatic products, and beef products, forming a comprehensive and well-defined production capacity matrix. Concurrently, the construction of the Company's food production base in Danzhou, Hainan Province, officially commenced. This base will further expand its geographical coverage, optimize the supply chain's radiation radius, and strengthen the national production capacity layout and logistics reach.This solid industrial foundation continuously improves the operational efficiency of the digitalized supply chain. Based on the supply chain system operating from factory to central warehouse and to retail stores, the Company can monitor supply and demand dynamics from the procurement end to the store end, and closely manage inventory levels, thereby achieving efficient management of the entire supply chain. As of 31 December 2025, the Company had deployed 20 digitalized central warehouses across China, achieving swift product circulation through digital stock and barcode management. Simultaneously, the digitalization of the supply chain covering core segments such as production, procurement, warehousing, and logistics allows for precise monitoring of supply-demand dynamics and inventory levels, ensuring the timely supply of products to stores in the Chinese mainland. This comprehensively enhances the overall operational efficiency of the supply chain, solidifying core barriers in cost control and quality assurance.Six Core Strategic Directions: Continuously Advancing Business UpgradesIn 2026, Guoquan targets that the total number of stores will exceed 14,500, representing a net increase of over 2,934 stores, with an estimated store closure rate of less than 4%. It targets high-single-digit growth in store efficiency, and the number of registered members is targeted to exceed 95 million. The Company targets that the growth rate of core operating profit will be significantly higher than that of its revenue.First, Fully expand the sales network with four stores jointly advancing with concerted efforts. Guoquan will continue to build a multi-level sales network, accelerate the expansion of large stores in townships, practice the philosophy of "food equality", and precisely meet the consumption needs of residents in county and township markets. Concurrently, it will explore innovative store formats and upgrade the franchisee management system to build a symbiotic and mutually beneficial franchise ecosystem.Second, Deepen the strategy of community central kitchen to expand community consumption scenarios. The Company will focus on creating food retail solutions for "four meals a day", continuously diversifying its product categories and building a more competitive product matrix to achieve organic sales growth while further consolidating its advantages in lower-tier market layout.Third, Deepen membership operation and IP to advance the community brand project. The Company will continue to advance refined membership operation, deeply integrate media resources such as popular TV commercials, offline community advertising and social media and e-commerce platforms (such as Douyin) to expand its membership base, and improve the membership rights system to enhance member loyalty and stickiness. Furthermore, it will further deepen the operation of its brand IP image "Guobao" to strengthen brand value and emotional resonance with consumers.Fourth, AI big data empower stores to innovate smart retail scenarios. By integrating Internet of Things, big data, and AI technology, the Company will drive the smart operation of stores with data. It will promote the in-depth integration of the Guoquan stir-fry business format with smart cooking machines, accurately analyze consumers' dining habits, optimize dish parameters and cooking procedures for smart cooking machines, realize the standardized production of stir-fry dishes, and optimize the consumer experience.Fifth, Continue to promote the industrial layout and strengthen the advantage of one-product-one-factory. Adhering to the "one-product-one-factory" strategy, Guoquan will further integrate upstream resources domestically and internationally, accelerate the construction of the food production base in Danzhou, Hainan Province, increase R&D investment, and launch more product portfolios with a high quality-price ratio.Sixth, Develop overseas markets in phases to deliver the good taste of China. Guoquan plans to explore and establish a presence in overseas regional markets in a phased manner to unlock long-term growth potential. Leveraging its core competitiveness, it will steadily advance its overseas market exploration. It also plans to take the lead in opening stores in Hong Kong Special Administrative Region, China to accumulate and gather operational experience, gradually achieving overseas product sales and enhancing global brand visibility.About Guoquan Food (Shanghai) CO., LTD. (2517.HK):Guoquan Food (Shanghai) Co., Ltd. (“Guoquan”; Stock Code: 2517.HK) is the leading one-stop home meal products brand in China, offering a variety of ready-to-eat, ready-to-heat, ready-to-cook and prepared ingredients, with a focus on at-home hotpot and barbecue products.  Leveraging Company’s robust supply chain capabilities, a strategic industrial layout with self-owned factories, a nationwide network of around 10,000 instant retail stores, and a carefully curated product portfolio, Company offer a variety of home meal products solution under the “Guoquan Shihui” brand, catering to different dining scenarios.This press release is issued by EverBloom (HK) Communications Consultants Group Limited on behalf of Guoquan Food (Shanghai) Co., Ltd. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-13

康哲藥業：磷酸蘆可替尼乳膏（百盧妥(R)）在中國多地實現白癜風首批處方落地

深圳, 2026年3月13日 - (亞太商訊 via SeaPRwire.com) - 2026年3月12日，康哲藥業控股有限公司 （「康哲藥業」）欣然宣佈，旗下德鎂醫藥有限公司（「德鎂醫藥」，專業聚焦皮膚健康的創新型醫藥企業，正申請於香港聯合交易所有限公司主板獨立上市），其創新處方藥磷酸蘆可替尼乳膏（百盧妥(R)）（「產品」，在美國、歐洲及加拿大以Opzelura(R)的名稱銷售）在全國30個省級行政區為白癜風患者開出首批處方，覆蓋包括復旦大學附屬華山醫院、上海市皮膚病醫院、南方醫科大學皮膚病醫院、成都市第二人民醫院、吉林大學白求恩第一醫院、中南大學湘雅二醫院、和睦家醫療集團等千家在皮膚健康及疾病管理領域具有影響力的公立及私立醫療機構*，並實現超1,300家線下藥店以及京東電商平臺同步可及。*醫院排名不分先後磷酸蘆可替尼乳膏為中國批准的首款用於白癜風治療的外用JAK抑制劑，今日正式拉開產品規模化臨床應用的序幕，標誌著我國白癜風治療領域實現突破性進展，邁入精准靶向治療的全新時代，產品將以經過臨床充分驗證的安全和有效性，點亮千萬白癜風患者複色希望。磷酸蘆可替尼乳膏的跨越式商業化進程，不僅彰顯了康哲藥業卓越的產品運營能力，更充分體現了國家藥政改革對臨床亟需創新藥加速可及的有力支持。受益於海南自貿港醫療健康產業整合性優勢，以及 「臨床急需進口」 政策，2023年8月，產品率先在海南博鼇樂城國際醫療旅遊先行區博鼇超級醫院啟動臨床應用，隨後試點應用逐步擴展至粵港澳大灣區、京津等區域指定醫療機構。在我國藥品真實世界數據應用試點有關程序，以及海南省藥品監督管理局與海南博鼇樂城國際醫療旅遊先行區管理局的支持下，產品通過「先行先試」臨床應用積累中國真實環境的診療數據，大大提速產品臨床、註冊和獲批上市進程，並成功於2026年1月30日取得《藥品註冊證書》（批准日期2026年1月27日）。獲批以來，僅耗時不到1.5個月（含春節假期），磷酸蘆可替尼乳膏便實現全國多地、多醫院首批處方集中落地，這亦是康哲藥業各部門、相關監管部門及合作夥伴高效聯動、共同努力的成果。在北京大興臨空區聯合管委會跨部門合作機制的有力保障下，產品具備進口條件後24小時內即完成了藥品通關審批、藥品抽樣及海關程序，並於7個工作日內取得藥品檢驗報告，全程跑出了高效務實的「中國創新藥加速度」。在此過程中，北京市藥監局主動開展商業規模批次政策的全流程指導，政務中心高效完成通關備案；北京市藥品檢驗研究院則通過前置方法學預檢驗、開闢創新藥專項通道，並在春節期間持續作業，全力確保檢驗進度高效推進；大興機場海關則提前對藥品申報要素進行專項指導，快速完成報關審核和藥品放行工作。各方協同、流程並聯，合力為磷酸蘆可替尼乳膏上市按下「快進鍵」，助力該臨床急需創新藥惠及廣大患者。隨著產品進入規模化臨床應用階段，將進一步強化德鎂醫藥皮膚疾病綜合解決方案及品牌價值。德鎂醫藥依託在皮膚健康領域的領先地位，將持續推進磷酸蘆可替尼乳膏使更多白癜風患者獲益，以創新之力堅定守護民眾皮膚健康。關於白癜風白癜風是一種慢性自身免疫性疾病，其特徵是皮膚色素脫失，其發病原因為產生色素的細胞即黑素細胞的缺失。脫色區域通常會隨著時間的推移而擴大，且該病症可能影響患者身體任何部位的皮膚，影響患者的容貌，尤其是面部、頸部等顯眼部位。根據一項對1,000多名已確診白癜風患者進行的研究，超過45%的患者面部受累，超過20%的患者頸部受累[1]。白色斑塊的明顯存在可能會讓患者認為自身的形象受到損害，進而嚴重影響其社會活動，精神疾病發病率顯著增加，因此白癜風的治療需求非常迫切[2]。據估算，中國約有1,030萬人患有白癜風，其中約820萬人患有非節段型白癜風[1]。現有療法，如外用糖皮質激素（TCS）及外用鈣調神經磷酸酶抑制劑（TCIs）存在臨床缺陷，長期用藥有不良反應或療效有限。磷酸蘆可替尼乳膏成功填補了白癜風靶向藥物治療的空白，具有重大標誌性意義。關於磷酸蘆可替尼乳膏的更多資訊磷酸蘆可替尼乳膏（Opzelura(R)）是Incyte開發的選擇性JAK1/JAK2抑制劑蘆可替尼製成的一種創新型乳膏，是經美國食品藥品監督管理局（FDA）及歐洲藥品管理局（EMA）批准的首款也是唯一一款用於非節段型白癜風複色的藥物[3,4]。在美國，產品獲批用於局部治療成人及12歲及以上兒童患者的非節段型白癜風；及其他外用藥控制不佳或不建議使用時，非免疫功能受損的2歲及以上兒童和成人輕中度特應性皮炎的局部短期和非持續性慢性治療。在歐洲，磷酸蘆可替尼乳膏被批准用於局部治療成人及12歲及以上青少年伴面部受累的非節段型白癜風。在中國，除白癜風適應症外，產品2歲及以上兒童和成人輕中度特應性皮炎（AD）適應症亦處於NDA審評階段， 且該項NDA已獲納入優先審評品種名單，有望加快產品AD適應症上市審評進程。康哲藥業於2022年12月2日，通過德鎂醫藥的附屬公司與Incyte就磷酸蘆可替尼乳膏訂立合作和許可協議（「許可協議」），獲得在中國大陸、香港特別行政區、澳門特別行政區、臺灣地區及東南亞十一國（「區域」）研發、註冊及商業化產品的獨家許可權利，以及在區域內生產產品的非獨家許可權利。德鎂醫藥的附屬公司已將磷酸蘆可替尼乳膏除中國大陸外的其他區域的相關權利再許可予康哲藥業（不包括德鎂醫藥及其附屬公司）。Incyte擁有磷酸蘆可替尼乳膏全球開發和商業化權利（已獨佔許可區域除外），在美國及歐洲以Opzelura(R)的名稱銷售。Opzelura(R)和Opzelura(R)標識是Incyte的註冊商標。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化，把控產品全生命週期管理的開放式平臺型企業，致力於提供有競爭力的產品和服務，滿足尚未滿足的醫療需求。康哲藥業專注於全球首創（FIC）及同類最優（BIC）的創新產品，並高效推進創新產品臨床研究開發和商業化進程，賦能科研成果向診療實踐的持續轉化，造福患者。康哲藥業聚焦專科領域，擁有被驗證的商業化能力，廣泛的渠道覆蓋和多疾病領域專家資源，核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展，以鞏固心腎代謝/消化/眼科/皮膚健康業務競爭力，帶來專科規模效率，其中皮膚健康業務（德鎂醫藥）已成為其細分領域的龍頭企業，並擬於聯交所獨立上市。同時，康哲藥業持續推動研產銷全產業鏈在東南亞及中東區域運營發展，以獲取新興市場的增量，助力集團實現高質量可持續發展。參考文獻/資料1.數據來自灼識諮詢報告2.Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis[J]. Journal of the European Academy of Dermatology and Venereology, 2018,32(8):1343-1351. DOI:10.1111/jdv.14739.3.FDA批准信息可在Incyte官網查詢，網址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream4.EMA批准信息可在Incyte官網查詢，網址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣，非廣告用途。本新聞不對任何藥品和-醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療資訊，請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請，不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制，但康哲藥業並無進行任何說明或保證、明述或暗示，或其他表述，對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述，該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證，存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測，康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-13

Revenue Triples in Four Years! Qunabox Group Reports RMB290 Million in Net Profit in 2025

HONG KONG, Mar 13, 2026 - (ACN Newswire via SeaPRwire.com) – Against the dual boost of a global technological revolution and China’s policies to expand domestic demand, the integration of AI with consumption scenarios has entered a phase of accelerated development. As a leading enterprise in China’s AI interactive marketing services sector, Qunabox Group (00917.HK) has seized industry opportunities and continued to deepen its core strategy of “AI + Consumption Scenarios”. The Company has achieved breakthroughs across multiple dimensions, including technological research and development, business deployment and global expansion, demonstrating strong development resilience and growth potential.On 12 March, Qunabox Group announced its 2025 financial results. According to the data, the Company maintained a robust growth momentum during the year, recording revenue of RMB1.663 billion, a year-on-year increase of 24.2%. More notably, the Company’s profitability continued to strengthen, with profit for the period reaching RMB290 million. The Company successfully turned losses into profits, marking the beginning of a new stage of development.The accounting loss recorded by Qunabox Group in 2024 was mainly attributable to changes in the fair value of preferred shares during the listing period. With the elimination of these accounting-related disturbances, the Company’s genuine intrinsic profitability has become increasingly evident, signaling that Qunabox has officially entered a golden period of growth driven by the explosive release of scale effects.Building a Solid Technological Foundation and Driving Qualitative Performance Growth Through Product InnovationIn 2025, Qunabox Group continued to deepen its “AI + Consumption Scenarios” strategy by increasing investment in underlying technologies and platform capabilities. R&D expenses rose significantly by 75% year-on-year, laying a solid technological foundation for the Company’s development. By building a unified AI technology middle platform and a modular capability system, the Group achieved improvements in both R&D efficiency and technology reusability.Its self-developed AI-OMNI multimodal neural integrated collaboration engine achieved key breakthroughs in perception, decision-making, and execution, becoming the core technological support for the Group’s product innovation. Leveraging these technological advantages, Qunabox Group systematically launched and upgraded a series of AI-powered interactive marketing products, including AI digital human shopping assistants, AI holographic marketing cabinets, an AIGC middle platform and resource library, AI Agent workstations, and AI data and strategy analytics solutions. These innovations provide reliable support for implementation across multiple businesses and scenarios, directly driving high-quality revenue growth.Business Synergy Fueling Expansion, Global Layout Unlocking New Growth PotentialBy business segment, the marketing services segment, the Group’s core business, recorded a year-on-year revenue increase of 27.8% in 2025 to reach RMB1.402 billion. Among them, the high-margin value-added marketing services delivered a standout performance, with revenue hitting RMB236 million, a year-on-year surge of 32.9%. Its revenue share continued to rise, driving the optimization of the overall revenue quality and gross margin structure. In 2025, the gross profit of this segment amounted to RMB875 million, up 28.8% year on year.As the strategic practice platform for the Group's "AI experiential consumption" initiative, the merchandise sales segment achieved continuous improvements in the commercial conversion efficiency of AI interactive terminals. This was accomplished through expanding the terminal network in high-potential cities such as Hangzhou, Chengdu and Ningbo, optimizing the product portfolio toward higher-margin items, and replacing traditional price promotions with intelligent interactive marketing. The segment has developed strong synergies with the core marketing services and become an important scenario for the commercial application of cutting-edge technologies. In 2025, revenue from the merchandise sales segment of Qunabox Group increased by 5.2% year on year to RMB194 million, while gross profit rose by 12.7% year on year to RMB49 million.The layout of lifestyle and innovative businesses has unlocked a new dimension of global growth for Qunabox Group. In 2025, focusing on "AI + Lifestyle", the Group expanded into the Middle East, Southeast Asia and Australia simultaneously. An overseas business department was established to oversee the full implementation of global operations, and strategic cooperation has been reached with key local partners in Dubai. Currently, Qunabox Group has completed the preliminary preparations for its AI-powered indoor entertainment spaces and obtained operating licenses in Dubai and Singapore. The establishment of overseas teams, product localization and refinement, as well as the integration of software and hardware systems are advancing steadily. The Group has also completed the validation of localized AI models, ensuring that its AI-driven interactive experiences can be accurately adapted to multilingual and cross-cultural scenarios. This lays a solid foundation for the scalable expansion of its overseas business, which is expected to become the Company’s second growth curve for performance.Expanding Customer Base: A New Journey for AI + Consumption ScenariosLeveraging its innovative and efficient business model and outstanding service capabilities, Qunabox Group has maintained sound and stable partnerships with brand clients. Additionally, the Company has expanded the application scenarios of its services, enriched and optimized its AI-driven interactive marketing products, developed data strategy solutions, and refined its marketing product portfolio and service model. As a result, the Company has continuously expanded its industry influence, deepened cooperation with high-quality clients, and steadily grown its premium client base, with both the number of brand clients and key accounts on the rise. In 2025, the total number of brand clients served by Qunabox Group increased to 332 for the full year, including 58 key accounts. The average revenue per key account grew by 15% year on year, reflecting a continuous rise in client value and further consolidating the foundation for the Company’s sustained performance growth.Supported by strong performance, Qunabox Group maintained a sound financial position and ample cash flow throughout the year. As at 31 December 2025, the Group’s cash and bank balances amounted to RMB1.506 billion, providing strong support for subsequent investments in technology, business expansion and global deployment.In summary, Qunabox Group’s outstanding performance in 2025 is the inevitable result of its years of deep engagement in AI technologies and its steadfast implementation of the “AI + Consumption Scenarios” strategy. The turnaround from loss to profit further demonstrates the sustainability of its business model and the growth potential of its profitability.Looking ahead, as the integration of artificial intelligence with physical consumption scenarios continues to deepen, a window of opportunity has emerged for the large-scale deployment of AI applications. With technology at its core and scenarios as its foundation, Qunabox Group is building a cross-regional, end-to-end AI lifestyle platform. Amid the accelerated cultivation of new quality productive forces, the Company, leveraging its technological barriers, scenario advantages and global vision, is well positioned to continue leading the industry transformation in the integration of AI and consumption and to achieve long-term sustainable development of its own. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2026-03-13